,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,1,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
2,3,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
3,3,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
4,5,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
5,5,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
6,7,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
7,7,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
8,9,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
9,9,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
10,11,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-18 Non-Small Cell Lung cell line,Confirmatory,,
11,13,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
12,13,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
13,15,1,1,,68737,1923,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
14,15,1,1,,144064,1923,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
15,17,1,1,,144064,1923,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the LXFL 529 Non-Small Cell Lung cell line,Confirmatory,,
16,19,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
17,19,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
18,21,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
19,21,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
20,23,1,1,,68737,1923,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
21,23,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
22,25,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
23,25,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
24,27,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M19-MEL Melanoma cell line,Confirmatory,,
25,29,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
26,29,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
27,31,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
28,31,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
29,33,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
30,33,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
31,35,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
32,37,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
33,37,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
34,39,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
35,39,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
36,41,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
37,41,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
38,43,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
39,43,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
40,45,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
41,45,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
42,47,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
43,47,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
44,49,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
45,49,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
46,51,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the XF 498 Central Nervous System cell line,Confirmatory,,
47,53,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
48,53,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
49,55,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
50,57,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-78 Central Nervous System cell line,Confirmatory,,
51,59,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
52,59,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
53,61,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DMS 273 Small Cell Lung cell line,Confirmatory,,
54,63,1,1,,144064,1923,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DMS 114 Small Cell Lung cell line,Confirmatory,,
55,65,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
56,65,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
57,67,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
58,67,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
59,69,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DLD-1 Colon cell line,Confirmatory,,
60,71,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
61,71,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
62,73,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
63,73,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
64,75,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM20L2 Colon cell line,Confirmatory,,
65,77,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
66,77,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
67,79,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
68,79,1,1,,144064,1923,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
69,81,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
70,81,1,1,,144064,1923,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
71,83,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
72,83,1,1,,144064,1923,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
73,85,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
74,85,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
75,87,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
76,87,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
77,89,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
78,89,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
79,91,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
80,91,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
81,93,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
82,93,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
83,95,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
84,95,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
85,97,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
86,97,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
87,99,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
88,99,1,1,,144064,1923,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
89,101,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
90,101,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
91,103,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
92,103,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
93,105,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
94,105,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
95,107,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
96,107,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
97,109,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
98,109,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
99,113,1,1,,144064,1923,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
100,115,1,1,,68737,1923,Unspecified,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
101,115,1,1,,144064,1923,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
102,119,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
103,119,1,1,,144064,1923,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
104,121,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
105,121,1,1,,144064,1923,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
106,123,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
107,123,1,1,,144064,1923,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
108,125,1,1,,68737,1923,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
109,125,1,1,,144064,1923,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
110,129,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,Confirmatory,,
111,129,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,Confirmatory,,
112,131,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
113,131,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
114,133,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
115,133,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
116,135,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF-631 Renal cell line,Confirmatory,,
117,137,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
118,137,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
119,139,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
120,139,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
121,141,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
122,141,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
123,143,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
124,143,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
125,145,1,1,,68737,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
126,145,1,1,,144064,1923,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
127,147,1,1,,144064,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad52 strain,Other,,
128,149,1,1,,144064,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the wt1 strain,Other,,
129,151,1,1,,144064,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50EPP+ strain,Other,,
130,153,1,1,,144064,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mgt1 strain,Other,,
131,155,1,1,,68737,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
132,155,1,1,,144064,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
133,155,1,1,,487229,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
134,157,1,1,,68737,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
135,157,1,1,,144064,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
136,157,1,1,,487229,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
137,159,1,1,,144064,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad14 strain,Other,,
138,161,1,1,,68737,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
139,161,1,1,,144064,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
140,161,1,1,,487229,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
141,163,1,1,,144064,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the CLN2oe strain,Other,,
142,165,1,1,,68737,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
143,165,1,1,,144064,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
144,165,1,1,,487229,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
145,167,1,1,,68737,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
146,167,1,1,,144064,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
147,167,1,1,,487229,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
148,169,1,1,,144064,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the wt2 strain,Other,,
149,171,1,1,,144064,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 strain,Other,,
150,173,1,1,,144064,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 strain,Other,,
151,175,1,1,,68737,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
152,175,1,1,,144064,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
153,175,1,1,,487229,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
154,177,1,1,,144064,1923,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad18 strain,Other,,
155,179,1,1,,144064,1923,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
156,179,1,1,,487229,1923,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
157,248,1,1,,68737,1923,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
158,328,1,1,,144064,1923,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
159,421,1,3,,17389213,1923,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
160,421,1,3,,17389852,1923,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
161,426,1,2,,17389213,1923,Inconclusive,,,,,Cell Viability - Jurkat,Confirmatory,,
162,426,1,2,,17389852,1923,Inconclusive,,,,,Cell Viability - Jurkat,Confirmatory,,
163,427,1,1,,17389213,1923,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
164,427,1,1,,17389852,1923,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
165,433,1,1,,17389213,1923,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
166,433,1,1,,17389852,1923,Inconclusive,,,,,Cell Viability - HepG2,Confirmatory,,
167,434,1,2,,17389213,1923,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
168,434,1,2,,17389852,1923,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
169,435,1,2,,17389213,1923,Active,,,,,Cell Viability - SK-N-SH,Confirmatory,,
170,435,1,2,,17389852,1923,Active,,,,,Cell Viability - SK-N-SH,Confirmatory,,
171,445,3,1,,17389213,1923,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
172,445,3,1,,17389852,1923,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
173,530,1,1,,17389213,1923,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
174,530,1,1,,17389852,1923,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
175,540,1,1,,17389213,1923,Inconclusive,,,,,Cell Viability - N2a,Confirmatory,,
176,540,1,1,,17389852,1923,Active,,,,,Cell Viability - N2a,Confirmatory,,
177,541,1,1,,17389213,1923,Active,,,,,Cell Viability - NIH 3T3,Confirmatory,,
178,541,1,1,,17389852,1923,Active,,,,,Cell Viability - NIH 3T3,Confirmatory,,
179,542,1,1,,17389213,1923,Inconclusive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
180,542,1,1,,17389852,1923,Inconclusive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
181,543,1,1,,17389213,1923,Active,,,,,Cell Viability - H-4-II-E,Confirmatory,,
182,543,1,1,,17389852,1923,Active,,,,,Cell Viability - H-4-II-E,Confirmatory,,
183,544,2,1,,17389213,1923,Active,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
184,544,2,1,,17389852,1923,Inconclusive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
185,545,1,1,,17389213,1923,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
186,545,1,1,,17389852,1923,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
187,546,1,1,,17389213,1923,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
188,546,1,1,,17389852,1923,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
189,584,1,3,,17389213,1923,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
190,584,1,3,,17389852,1923,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
191,585,1,4,,17389213,1923,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
192,585,1,4,,17389852,1923,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
193,595,1,3,,17389213,1923,Active,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
194,595,1,3,,17389852,1923,Active,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
195,596,1,2,,17389213,1923,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
196,596,1,2,,17389852,1923,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
197,603,1,2,,17389213,1923,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
198,603,1,2,,17389852,1923,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
199,605,1,2,,17389213,1923,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
200,605,1,2,,17389852,1923,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
201,654,1,1,,17389213,1923,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
202,654,1,1,,17389852,1923,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
203,655,1,1,,17389213,1923,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
204,655,1,1,,17389852,1923,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
205,656,1,1,,17389213,1923,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
206,656,1,1,,17389852,1923,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
207,657,1,1,,17389213,1923,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
208,657,1,1,,17389852,1923,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
209,658,1,1,,17389213,1923,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
210,658,1,1,,17389852,1923,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
211,659,1,1,,17389213,1923,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
212,659,1,1,,17389852,1923,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
213,660,1,1,,17389213,1923,Inconclusive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
214,660,1,1,,17389852,1923,Inconclusive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
215,661,1,1,,17389213,1923,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
216,661,1,1,,17389852,1923,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
217,662,1,1,,17389213,1923,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
218,662,1,1,,17389852,1923,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
219,663,1,1,,17389213,1923,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
220,663,1,1,,17389852,1923,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
221,664,1,1,,17389213,1923,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
222,664,1,1,,17389852,1923,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
223,665,1,1,,17389213,1923,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
224,665,1,1,,17389852,1923,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
225,666,1,1,,17389213,1923,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
226,666,1,1,,17389852,1923,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
227,667,1,1,,17389213,1923,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
228,667,1,1,,17389852,1923,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
229,712,1,4,,24724293,1923,Inactive,4261762.0,3326.0,50.0,IC50,Tumor Hsp90 Inhibitors Dose Response Confirmation,Confirmatory,,
230,712,1,4,,24724293,1923,Inactive,154146191.0,3320.0,50.0,IC50,Tumor Hsp90 Inhibitors Dose Response Confirmation,Confirmatory,,
231,875,1,2,,17389213,1923,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
232,875,1,2,,17389852,1923,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
233,880,2,1,,17389213,1923,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
234,880,2,1,,17389213,1923,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
235,880,2,1,,17389852,1923,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
236,880,2,1,,17389852,1923,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
237,881,2,2,,17389213,1923,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
238,881,2,2,,17389852,1923,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
239,884,1,2,,17389213,1923,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
240,884,1,2,,17389852,1923,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
241,885,1,2,,17389213,1923,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
242,885,1,2,,17389852,1923,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
243,886,1,2,,17389213,1923,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
244,886,1,2,,17389213,1923,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
245,886,1,2,,17389852,1923,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
246,886,1,2,,17389852,1923,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
247,887,1,2,,17389213,1923,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
248,887,1,2,,17389852,1923,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
249,889,1,3,,17389213,1923,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
250,889,1,3,,17389852,1923,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
251,892,1,2,,17389213,1923,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
252,892,1,2,,17389852,1923,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
253,893,1,2,,17389213,1923,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
254,893,1,2,,17389213,1923,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
255,893,1,2,,17389852,1923,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
256,893,1,2,,17389852,1923,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
257,894,2,1,,17389213,1923,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
258,894,2,1,,17389852,1923,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
259,900,1,3,,17389213,1923,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
260,900,1,3,,17389852,1923,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
261,902,1,2,,17389213,1923,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
262,902,1,2,,17389852,1923,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
263,912,1,2,,17389213,1923,Inconclusive,21392848.0,,1.0,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
264,912,1,2,,17389852,1923,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
265,921,1,2,,17389213,1923,Active,,,6.3096,Potency,Cell Viability - LYMP2-001,Confirmatory,,
266,921,1,2,,17389852,1923,Active,,,6.3096,Potency,Cell Viability - LYMP2-001,Confirmatory,,
267,923,1,2,,17389213,1923,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
268,923,1,2,,17389852,1923,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
269,924,1,2,,17389213,1923,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
270,924,1,2,,17389852,1923,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
271,925,1,2,,17389213,1923,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
272,925,1,2,,17389852,1923,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
273,926,1,2,,17389213,1923,Inconclusive,38016895.0,7253.0,19.9526,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
274,926,1,2,,17389852,1923,Inconclusive,38016895.0,7253.0,39.8107,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
275,938,1,2,,17389213,1923,Inactive,38016895.0,7253.0,19.9526,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
276,938,1,2,,17389852,1923,Inconclusive,38016895.0,7253.0,39.8107,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
277,946,1,2,,17389213,1923,Inconclusive,,,31.6228,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
278,946,1,2,,17389852,1923,Active,,,39.8107,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
279,947,1,2,,17389213,1923,Inconclusive,,,31.6228,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
280,947,1,2,,17389852,1923,Inconclusive,,,31.6228,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
281,948,1,2,,17389213,1923,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
282,948,1,2,,17389852,1923,Inconclusive,,,31.6228,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
283,955,1,2,,17389213,1923,Inconclusive,,,12.5893,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
284,955,1,2,,17389852,1923,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
285,960,1,2,,17389213,1923,Active,,,15.8489,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
286,960,1,2,,17389852,1923,Active,,,15.8489,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
287,961,1,2,,17389213,1923,Inconclusive,,,25.1189,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
288,961,1,2,,17389852,1923,Inconclusive,,,25.1189,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
289,962,1,2,,17389213,1923,Inconclusive,,,25.1189,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
290,962,1,2,,17389852,1923,Inconclusive,,,31.6228,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
291,963,1,2,,17389213,1923,Inconclusive,,,25.1189,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
292,963,1,2,,17389852,1923,Inconclusive,,,25.1189,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
293,964,1,2,,17389213,1923,Active,,,31.6228,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
294,964,1,2,,17389852,1923,Active,,,39.8107,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
295,965,1,2,,17389213,1923,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP2-003,Confirmatory,,
296,965,1,2,,17389852,1923,Active,,,12.5893,Potency,Cell Viability - LYMP2-003,Confirmatory,,
297,966,1,2,,17389213,1923,Active,,,15.8489,Potency,Cell Viability - LYMP2-004,Confirmatory,,
298,966,1,2,,17389852,1923,Active,,,12.5893,Potency,Cell Viability - LYMP2-004,Confirmatory,,
299,967,1,2,,17389213,1923,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP2-005,Confirmatory,,
300,967,1,2,,17389852,1923,Inconclusive,,,12.5893,Potency,Cell Viability - LYMP2-005,Confirmatory,,
301,968,1,2,,17389213,1923,Inconclusive,,,12.5893,Potency,Cell Viability - LYMP2-009,Confirmatory,,
302,968,1,2,,17389852,1923,Active,,,10.0,Potency,Cell Viability - LYMP2-009,Confirmatory,,
303,969,1,2,,17389213,1923,Inconclusive,,,19.9526,Potency,Cell Viability - LYMP2-011,Confirmatory,,
304,969,1,2,,17389852,1923,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP2-011,Confirmatory,,
305,970,1,2,,17389213,1923,Active,,,15.8489,Potency,Cell Viability - LYMP2-013,Confirmatory,,
306,970,1,2,,17389852,1923,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP2-013,Confirmatory,,
307,971,1,2,,17389213,1923,Active,,,12.5893,Potency,Cell Viability - LYMP2-015,Confirmatory,,
308,971,1,2,,17389852,1923,Active,,,12.5893,Potency,Cell Viability - LYMP2-015,Confirmatory,,
309,972,1,2,,17389213,1923,Active,,,12.5893,Potency,Cell Viability - LYMP2-017,Confirmatory,,
310,972,1,2,,17389852,1923,Active,,,10.0,Potency,Cell Viability - LYMP2-017,Confirmatory,,
311,973,1,2,,17389213,1923,Active,,,10.0,Potency,Cell Viability - LYMP2-019,Confirmatory,,
312,973,1,2,,17389852,1923,Active,,,10.0,Potency,Cell Viability - LYMP2-019,Confirmatory,,
313,974,1,2,,17389213,1923,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP2-021,Confirmatory,,
314,974,1,2,,17389852,1923,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP2-021,Confirmatory,,
315,975,1,2,,17389213,1923,Active,,,25.1189,Potency,Cell Viability - LYMP2-023,Confirmatory,,
316,975,1,2,,17389852,1923,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP2-023,Confirmatory,,
317,976,1,2,,17389213,1923,Active,,,31.6228,Potency,Cell Viability - LYMP2-025,Confirmatory,,
318,976,1,2,,17389852,1923,Active,,,19.9526,Potency,Cell Viability - LYMP2-025,Confirmatory,,
319,977,1,2,,17389213,1923,Active,,,25.1189,Potency,Cell Viability - LYMP2-002,Confirmatory,,
320,977,1,2,,17389852,1923,Active,,,15.8489,Potency,Cell Viability - LYMP2-002,Confirmatory,,
321,978,1,2,,17389213,1923,Active,,,25.1189,Potency,Cell Viability - LYMP2-006,Confirmatory,,
322,978,1,2,,17389852,1923,Active,,,15.8489,Potency,Cell Viability - LYMP2-006,Confirmatory,,
323,979,1,2,,17389213,1923,Active,,,15.8489,Potency,Cell Viability - LYMP2-007,Confirmatory,,
324,979,1,2,,17389852,1923,Active,,,15.8489,Potency,Cell Viability - LYMP2-007,Confirmatory,,
325,980,1,2,,17389213,1923,Active,,,15.8489,Potency,Cell Viability - LYMP2-008,Confirmatory,,
326,980,1,2,,17389852,1923,Active,,,12.5893,Potency,Cell Viability - LYMP2-008,Confirmatory,,
327,981,1,2,,17389213,1923,Active,,,12.5893,Potency,Cell Viability - LYMP2-010,Confirmatory,,
328,981,1,2,,17389852,1923,Active,,,10.0,Potency,Cell Viability - LYMP2-010,Confirmatory,,
329,982,1,2,,17389213,1923,Active,,,15.8489,Potency,Cell Viability - LYMP2-012,Confirmatory,,
330,982,1,2,,17389852,1923,Active,,,10.0,Potency,Cell Viability - LYMP2-012,Confirmatory,,
331,983,1,2,,17389213,1923,Active,,,15.8489,Potency,Cell Viability - LYMP2-014,Confirmatory,,
332,983,1,2,,17389852,1923,Active,,,12.5893,Potency,Cell Viability - LYMP2-014,Confirmatory,,
333,984,1,2,,17389213,1923,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP2-016,Confirmatory,,
334,984,1,2,,17389852,1923,Active,,,15.8489,Potency,Cell Viability - LYMP2-016,Confirmatory,,
335,985,1,2,,17389213,1923,Active,,,12.5893,Potency,Cell Viability - LYMP2-018,Confirmatory,,
336,985,1,2,,17389852,1923,Active,,,10.0,Potency,Cell Viability - LYMP2-018,Confirmatory,,
337,986,1,2,,17389213,1923,Active,,,12.5893,Potency,Cell Viability - LYMP2-020,Confirmatory,,
338,986,1,2,,17389852,1923,Active,,,10.0,Potency,Cell Viability - LYMP2-020,Confirmatory,,
339,987,1,2,,17389213,1923,Active,,,10.0,Potency,Cell Viability - LYMP2-022,Confirmatory,,
340,987,1,2,,17389852,1923,Active,,,6.3096,Potency,Cell Viability - LYMP2-022,Confirmatory,,
341,988,1,2,,17389213,1923,Active,,,7.9433,Potency,Cell Viability - LYMP2-024,Confirmatory,,
342,988,1,2,,17389852,1923,Active,,,7.9433,Potency,Cell Viability - LYMP2-024,Confirmatory,,
343,989,1,2,,17389213,1923,Inconclusive,,,25.1189,Potency,Cell Viability - LYMP2-026,Confirmatory,,
344,989,1,2,,17389852,1923,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP2-026,Confirmatory,,
345,993,1,2,,17389213,1923,Inconclusive,,,25.1189,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
346,993,1,2,,17389852,1923,Active,,,25.1189,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
347,994,1,2,,17389213,1923,Inconclusive,,,31.6228,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
348,994,1,2,,17389852,1923,Inconclusive,,,31.6228,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
349,995,1,2,,17389213,1923,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
350,995,1,2,,17389852,1923,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
351,1030,2,1,,17389213,1923,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
352,1030,2,1,,17389852,1923,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
353,1189,1,5,,48413889,1923,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
354,1194,1,3,,48413889,1923,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
355,1199,1,3,,48413889,1923,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
356,1205,1,4,,48413889,1923,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
357,1208,1,3,,48413889,1923,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
358,1452,1,1,,17389213,1923,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
359,1452,1,1,,17389852,1923,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
360,1457,1,1,,17389213,1923,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
361,1457,1,1,,17389852,1923,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
362,1458,1,1,,17389213,1923,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
363,1458,1,1,,17389852,1923,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
364,1469,1,1,,17389213,1923,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
365,1469,1,1,,17389852,1923,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
366,1471,2,1,,17389213,1923,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
367,1471,2,1,,17389852,1923,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
368,1476,2,1,,17389213,1923,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
369,1476,2,1,,17389852,1923,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
370,1477,1,1,,17389213,1923,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
371,1477,1,1,,17389852,1923,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
372,1478,2,1,,17389213,1923,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
373,1478,2,1,,17389852,1923,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
374,1479,1,2,,17389213,1923,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
375,1479,1,2,,17389852,1923,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
376,1490,2,1,,49826123,1923,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
377,1511,1,3,,49826123,1923,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
378,1527,1,3,,49826123,1923,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
379,1529,1,1,,49826123,1923,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
380,1530,1,1,,49826123,1923,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
381,1531,1,1,,49826123,1923,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
382,1554,1,1,,49826123,1923,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
383,1556,1,4,,49826123,1923,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
384,1565,2,2,,49826123,1923,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
385,1566,2,3,,49826123,1923,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
386,1578,3,2,,49826123,1923,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
387,1580,1,1,,8149464,1923,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
388,1581,1,1,,8149464,1923,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
389,1582,1,1,,8149464,1923,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
390,1583,1,1,,8149464,1923,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
391,1584,1,1,,8149464,1923,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
392,1585,1,1,,8149464,1923,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
393,1586,1,1,,8149464,1923,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
394,1587,1,1,,8149464,1923,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
395,1588,1,1,,8149464,1923,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
396,1589,1,1,,8149464,1923,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
397,1590,1,1,,8149464,1923,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
398,1593,1,1,,8149464,1923,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
399,1594,1,1,,8149464,1923,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
400,1595,1,1,,8149464,1923,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
401,1596,1,1,,8149464,1923,Active,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
402,1597,1,1,,8149464,1923,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
403,1598,1,1,,8149464,1923,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
404,1599,1,1,,8149464,1923,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
405,1600,1,1,,8149464,1923,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
406,1601,1,1,,8149464,1923,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
407,1602,1,1,,8149464,1923,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
408,1603,1,1,,8149464,1923,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
409,1604,1,1,,8149464,1923,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
410,1605,1,1,,8149464,1923,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
411,1606,1,1,,8149464,1923,Active,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
412,1607,1,1,,8149464,1923,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
413,1608,1,1,,8149464,1923,Active,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
414,1609,1,1,,8149464,1923,Active,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
415,1610,1,1,,8149464,1923,Active,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
416,1612,1,1,,8149464,1923,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
417,1613,1,1,,8149464,1923,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
418,1614,1,1,,8149464,1923,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
419,1616,1,1,,8149464,1923,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
420,1621,1,2,,49826123,1923,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
421,1631,3,1,,49826123,1923,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
422,1634,3,1,,49826123,1923,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
423,1654,2,2,,49826123,1923,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
424,1656,2,2,,49826123,1923,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
425,1662,1,2,,49826123,1923,Active,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
426,1663,1,2,,49826123,1923,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
427,1672,1,3,,49826123,1923,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
428,1700,1,2,,49826123,1923,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
429,1706,1,2,,49826123,1923,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
430,1721,1,2,,49826123,1923,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
431,1722,1,2,,49826123,1923,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
432,1766,1,1,,49826123,1923,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
433,1766,1,1,,49826123,1923,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
434,1768,1,1,,49826123,1923,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
435,1768,1,1,,49826123,1923,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
436,1777,3,2,,49826123,1923,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
437,1778,3,3,,49826123,1923,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
438,1779,2,2,,49826123,1923,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
439,1789,1,2,,49826123,1923,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
440,1800,1,2,,49826123,1923,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
441,1813,1,2,,49826123,1923,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
442,1814,1,2,,49826123,1923,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
443,1817,2,2,,49826123,1923,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
444,1822,1,3,,49826123,1923,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
445,1825,1,1,,49826123,1923,Active,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
446,1832,2,1,,49826123,1923,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
447,1835,1,2,,49826123,1923,Inactive,487738.0,3757.0,,,Confirmatory screen for compounds that protect hERG from block by proarrhythmic agents,Screening,,
448,1839,1,2,,49826123,1923,Inactive,487738.0,3757.0,,,Counter screen for compounds that protect hERG from block by proarrhythmic agents,Screening,,
449,1845,1,2,,49826123,1923,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
450,1850,2,1,,49826123,1923,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
451,1861,2,1,,49826123,1923,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
452,1863,2,1,,49826123,1923,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
453,1875,2,1,,49826123,1923,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
454,1885,2,1,,49826123,1923,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
455,1899,1,3,,49826123,1923,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
456,1903,2,3,,49826123,1923,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
457,1906,1,3,,49826123,1923,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
458,1910,1,2,,49826123,1923,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
459,1933,1,1,,49826123,1923,Inactive,,,150.0,EC50,Luminescence Cell-Based Dose Response HTS to Identify Compounds Cytotoxic to BJ-TERT RAS-Independent Fibroblast,Confirmatory,,
460,1934,1,1,,49826123,1923,Active,,,17.894000000000002,EC50,Luminescence Cell-Based Dose Response HTS to Identify Compounds Cytotoxic to DRD Non-Viral Oncogenic Fibroblast,Confirmatory,,
461,1935,1,1,,49826123,1923,Inactive,,,150.0,EC50,Luminescence Cell-Based Dose Response HTS to Identify Compounds Cytotoxic to BJ-TERT-LT-ST RAS-Independent Fibroblast,Confirmatory,,
462,1936,1,1,,49826123,1923,Active,,,124.595,EC50,Luminescence Cell-Based Dose Confirmation HTS to Identify Compounds Cytotoxic to BJeLR RAS-Dependent Fibroblast,Confirmatory,,
463,1942,1,1,,49826123,1923,Inactive,18959272.0,170848.0,,,KCNQ2 Counter screen for compounds that protect hERG from block by proarrhythmic agents,Screening,,
464,1946,1,1,,49826123,1923,Inactive,18959272.0,170848.0,,,KCNQ2 Counter screen for inhibitors that protect hERG from block by proarrhythmic agents,Screening,,
465,1947,1,2,,49826123,1923,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
466,1948,1,1,,17389213,1923,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
467,1948,1,1,,17389852,1923,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
468,1950,1,3,,49826123,1923,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
469,1961,2,2,,49826123,1923,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
470,1962,1,2,,49826123,1923,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
471,1974,1,2,,49826123,1923,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
472,1979,1,1,,49826123,1923,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
473,1984,1,3,,49826123,1923,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
474,1986,1,2,,49826123,1923,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
475,1987,1,2,,49826123,1923,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
476,2006,3,2,,49826123,1923,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
477,2006,3,2,,49826123,1923,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
478,2006,3,2,,49826123,1923,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
479,2012,3,2,,49826123,1923,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
480,2013,2,2,,49826123,1923,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
481,2014,3,2,,49826123,1923,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
482,2016,1,3,,49826123,1923,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
483,2023,1,3,,49826123,1923,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
484,2025,1,3,,49826123,1923,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
485,2029,1,3,,49826123,1923,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
486,2052,2,1,,49826123,1923,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
487,2057,1,2,,49826123,1923,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
488,2058,3,2,,49826123,1923,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
489,2066,1,4,,49826123,1923,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
490,2071,2,2,,49826123,1923,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
491,2073,2,3,,49826123,1923,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
492,2073,2,3,,49826123,1923,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
493,2094,1,2,,49826123,1923,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
494,2094,1,2,,49826123,1923,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
495,2094,1,2,,49826123,1923,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
496,2097,1,2,,49826123,1923,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
497,2098,1,1,,49826123,1923,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
498,2099,1,1,,49826123,1923,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
499,2100,1,1,,49826123,1923,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
500,2101,1,1,,17389213,1923,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
501,2101,1,1,,17389852,1923,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
502,2101,1,1,,49826123,1923,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
503,2107,1,1,,17389213,1923,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
504,2107,1,1,,17389852,1923,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
505,2112,1,1,,17389213,1923,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
506,2112,1,1,,17389852,1923,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
507,2120,1,1,,17389213,1923,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
508,2120,1,1,,17389852,1923,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
509,2129,1,2,,49826123,1923,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
510,2130,1,3,,49826123,1923,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
511,2156,2,2,,49826123,1923,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
512,2174,1,3,,49826123,1923,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
513,2177,1,3,,49826123,1923,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
514,2216,1,3,,49826123,1923,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
515,2227,1,2,,49826123,1923,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
516,2234,1,2,,49826123,1923,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
517,2235,1,2,,49826123,1923,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
518,2237,1,2,,49826123,1923,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
519,2239,1,2,,49826123,1923,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
520,2240,1,1,,85789208,1923,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
521,2241,1,1,,85789208,1923,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
522,2247,1,2,,49826123,1923,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
523,2275,1,1,,85789208,1923,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
524,2280,2,3,,49826123,1923,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
525,2288,1,1,,49826123,1923,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
526,2289,1,1,,49826123,1923,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
527,2300,1,3,,49826123,1923,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
528,2313,1,1,,85789208,1923,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
529,2314,1,2,,26752756,1923,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
530,2314,1,2,,26752756,1923,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
531,2314,1,2,,49826123,1923,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
532,2314,1,2,,49826123,1923,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
533,2315,1,2,,26752756,1923,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
534,2315,1,2,,26752756,1923,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
535,2315,1,2,,49826123,1923,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
536,2315,1,2,,49826123,1923,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
537,2322,1,1,,85789208,1923,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
538,2326,1,1,,49826123,1923,Inactive,194352380.0,,11.2202,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
539,2330,1,1,,85789208,1923,Active,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
540,2391,1,1,,49826123,1923,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
541,2435,1,2,,49826123,1923,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
542,2445,1,2,,49826123,1923,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
543,2451,1,2,,49826123,1923,Inconclusive,122920737.0,,31.6228,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
544,2462,1,1,,49826123,1923,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
545,2462,1,1,,49826123,1923,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
546,2472,1,2,,49826123,1923,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
547,2517,2,1,,17389213,1923,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
548,2517,2,1,,17389852,1923,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
549,2517,2,1,,49826123,1923,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
550,2528,1,2,,49826123,1923,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
551,2546,1,1,,17389213,1923,Active,188536040.0,19885.0,2.8184,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
552,2546,1,1,,17389852,1923,Active,188536040.0,19885.0,2.2387,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
553,2546,1,1,,49826123,1923,Active,188536040.0,19885.0,3.5481,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
554,2549,1,1,,17389213,1923,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
555,2549,1,1,,17389852,1923,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
556,2550,1,3,,49826123,1923,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
557,2551,1,1,,17389213,1923,Active,188536040.0,19885.0,0.8913,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
558,2551,1,1,,17389852,1923,Active,188536040.0,19885.0,0.631,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
559,2551,1,1,,49826123,1923,Active,188536040.0,19885.0,2.2387,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
560,2553,1,2,,49826123,1923,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
561,2557,1,3,,49826123,1923,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
562,2606,1,2,,49826123,1923,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
563,2629,1,1,,49826123,1923,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
564,2642,1,2,,49826123,1923,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
565,2648,1,2,,49826123,1923,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
566,2650,2,1,,49826123,1923,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
567,2661,1,1,,49826123,1923,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
568,2662,2,1,,49826123,1923,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
569,2675,1,1,,49826123,1923,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
570,2676,1,2,,49826123,1923,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
571,2685,1,1,,49826123,1923,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
572,2690,1,2,,49826123,1923,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
573,2716,1,1,,49826123,1923,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
574,2717,1,2,,49826123,1923,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
575,2718,1,1,,49826123,1923,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
576,2751,2,2,,49826123,1923,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
577,2796,1,4,,49826123,1923,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
578,2797,1,2,,49826123,1923,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
579,24627,3,4,,103284327,1923,Unspecified,,,,,Compound was tested for their chelating potential (free ligand) determined by distribution coefficient method.,Other,8809155.0,
580,24628,3,4,,103284327,1923,Unspecified,,,,,Compound was tested for their chelating potential with Indium-III complex determined by distribution coefficient method.,Other,8809155.0,
581,24629,3,4,,103284327,1923,Unspecified,,,,,Compound was tested for their chelating potential with Iron-III complex determined by distribution coefficient method.,Other,8809155.0,
582,24630,3,4,,103284327,1923,Unspecified,,,,,Compound was tested for their chelating potential with gallium-III complex determined by distribution coefficient method.,Other,8809155.0,
583,28931,4,4,,103284327,1923,Unspecified,,,,,Logarithm of cumulative stability constant was determined,Other,8355246.0,
584,72027,6,2,,103284327,1923,Active,,,2.1,IC50,Inhibit growth of FM3A cells by 50%,Confirmatory,1732542.0,
585,72038,4,4,,103284327,1923,Unspecified,,,,,Ability to induce dNTP pool imbalance at 41 uM dose was tested; significant imbalance in the intracellular dNTP pool in FM3A cells,Other,1732542.0,
586,96370,6,2,,103284327,1923,Active,,,2.1,IC50,Inhibit growth of KB cells by 50%,Confirmatory,1732542.0,
587,100077,3,3,,103284327,1923,Unspecified,,,,,Percentage of release of lactic dehydrogenase from rat hepatocytes,Other,8355246.0,
588,154261,3,4,,103284327,1923,Unspecified,,,,,Tested in vivo for the antitumor activity against P388 in mice after intraperitoneal administration of 100 mg/kg dose; T/C= treated/control,Other,1732542.0,
589,154398,4,4,,103284327,1923,Unspecified,,,,,Compound was tested in vivo for the antitumor activity against P388 leukemia cells in mice after intraperitoneal administration of 200 mg/kg dose; T/C= treated/control,Other,1732542.0,
590,170381,3,3,,103284327,1923,Unspecified,,,,,Percentage of mobilization of iron in 2 hours from rat hepatocytes,Other,8355246.0,
591,276761,4,4,,103284327,1923,Unspecified,,,,IC50,Inhibition of PrP-res formation in mouse ScN2a cells relative to control,Confirmatory,16987659.0,
592,276762,4,4,,103284327,1923,Unspecified,,,,IC50,Inhibition of PrP-res formation in prion Fukuoka1 strain infected mouse N2a#58 cells relative to control,Confirmatory,16987659.0,
593,276765,3,4,,103284327,1923,Active,,,,,Cytotoxicity against mouse ScN2a cells at 100 uM,Other,16987659.0,
594,276766,3,3,,103284327,1923,Active,,,,,Cytotoxicity against prion Fukuoka1 strain infected mouse N2a#58 cells at 100 uM,Other,16987659.0,
595,283249,6,2,,103284327,1923,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra ATCC 25177 by microplate alamar blue assay,Other,17178795.0,
596,346257,13,2,,103284327,1923,Unspecified,93141324.0,,350.0,IC50,Inhibition of Bacillus thermoproteolyticus thermolysin,Confirmatory,19072688.0,
597,346258,11,1,,103284327,1923,Unspecified,93141324.0,,,Km,Activity of Bacillus thermoproteolyticus thermolysin,Confirmatory,19072688.0,
598,346259,3,9,,103284327,1923,Unspecified,93141324.0,,,,Inhibition of Bacillus thermoproteolyticus thermolysin at 10 uM,Other,19072688.0,
599,421768,3,3,,103284327,1923,Active,,,,,Effect on trxB2 RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis,Other,19093848.0,
600,421769,3,3,,103284327,1923,Active,,,,,Effect on trxC RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis,Other,19093848.0,
601,421770,3,3,,103284327,1923,Active,,,,,Upregulation of clpB RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis,Other,19093848.0,
602,421771,3,3,,103284327,1923,Active,,,,,Upregulation of sigH RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis,Other,19093848.0,
603,421772,3,3,,103284327,1923,Active,,,,,Upregulation of dnaJ RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis,Other,19093848.0,
604,421773,3,3,,103284327,1923,Active,,,,,Upregulation of dnaK RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis,Other,19093848.0,
605,421774,3,3,,103284327,1923,Active,,,,,Upregulation of hsp RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis,Other,19093848.0,
606,421775,3,3,,103284327,1923,Active,,,,,Upregulation of Rv0331 RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis,Other,19093848.0,
607,421776,3,3,,103284327,1923,Active,,,,,Upregulation of Rv3463 RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis,Other,19093848.0,
608,421777,3,3,,103284327,1923,Active,,,,,Upregulation of Rv3054c RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis,Other,19093848.0,
609,421778,3,3,,103284327,1923,Active,,,,,Upregulation of Rv1334 RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis,Other,19093848.0,
610,421779,3,3,,103284327,1923,Active,,,,,Upregulation of Rv1335 RNA expression in Mycobacterium tuberculosis H37Rv ATCC 27294 at 2 to 10 ug/ml after 6 hrs by microarray analysis,Other,19093848.0,
611,434955,1,2,,49826123,1923,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
612,434959,1,1,,85789208,1923,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
613,434962,1,2,,49826123,1923,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
614,434989,1,1,,49826123,1923,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
615,435030,1,2,,49826123,1923,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
616,435030,1,2,,49826123,1923,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
617,443993,8,5,,103284327,1923,Unspecified,123948.0,3620.0,750.0,IC50,Inhibition of human recombinant IDO expressed in Escherichia coli BL21 AI,Confirmatory,20055453.0,
618,447578,3,4,,103284327,1923,Unspecified,2498443.0,3065.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
619,447578,3,4,,103284327,1923,Unspecified,3334210.0,8841.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
620,447578,3,4,,103284327,1923,Unspecified,19865267.0,9734.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
621,447578,3,4,,103284327,1923,Unspecified,26394832.0,79885.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
622,447578,3,4,,103284327,1923,Unspecified,27734403.0,83933.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
623,447578,3,4,,103284327,1923,Unspecified,29839394.0,55869.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
624,447578,3,4,,103284327,1923,Unspecified,30913097.0,51564.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
625,447578,3,4,,103284327,1923,Unspecified,68068066.0,3066.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
626,447578,3,4,,103284327,1923,Unspecified,205371758.0,10013.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
627,447578,3,4,,103284327,1923,Unspecified,259016348.0,9759.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
628,447578,3,4,,103284327,1923,Unspecified,296434519.0,10014.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
629,449728,1,2,,49826123,1923,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
630,449762,1,2,,49826123,1923,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
631,463079,1,2,,49826123,1923,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
632,463082,1,1,,49826123,1923,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
633,463111,1,1,,49826123,1923,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
634,463141,1,2,,49826123,1923,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
635,463165,1,1,,49826123,1923,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
636,463210,1,2,,49826123,1923,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
637,463254,1,1,,49826123,1923,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
638,485270,1,1,,49826123,1923,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
639,485272,1,1,,49826123,1923,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
640,485275,1,3,,49826123,1923,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
641,485281,1,1,,49826123,1923,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
642,485290,1,1,,17389213,1923,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
643,485290,1,1,,17389852,1923,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
644,485290,1,1,,26752756,1923,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
645,485294,1,1,,49826123,1923,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
646,485297,1,1,,49826123,1923,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
647,485298,1,1,,49826123,1923,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
648,485313,1,2,,49826123,1923,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
649,485314,1,1,,49826123,1923,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
650,485317,1,2,,49826123,1923,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
651,485341,1,1,,49826123,1923,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
652,485344,1,1,,49826123,1923,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
653,485347,1,2,,49826123,1923,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
654,485349,1,1,,49826123,1923,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
655,485353,2,1,,49826123,1923,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
656,485358,1,1,,49826123,1923,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
657,485364,1,1,,49826123,1923,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
658,485367,1,2,,49826123,1923,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
659,488837,1,1,,49826123,1923,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
660,488847,1,3,,49826123,1923,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
661,488890,1,2,,49826123,1923,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
662,488922,1,2,,49826123,1923,Active,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
663,488975,1,2,,49826123,1923,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
664,488977,1,2,,49826123,1923,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
665,489469,4,3,,103284327,1923,Unspecified,,,,,Inhibition of Escherichia coli MetAP at 25 uM,Other,20621724.0,
666,489470,5,2,,103284327,1923,Active,,,0.77,IC50,Inhibition of Escherichia coli MetAP,Confirmatory,20621724.0,
667,489471,4,3,,103284327,1923,Unspecified,,,,,Inhibition of Staphylococcus aureus MetAP at 25 uM,Other,20621724.0,
668,489472,5,2,,103284327,1923,Active,,,18.3,IC50,Inhibition of Staphylococcus aureus MetAP,Confirmatory,20621724.0,
669,489473,4,8,,103284327,1923,Unspecified,33302602.0,23173.0,,,Inhibition of human MetAP1 at 25 uM,Other,20621724.0,
670,489474,8,5,,103284327,1923,Active,33302602.0,23173.0,21.5,IC50,Inhibition of human MetAP1,Confirmatory,20621724.0,
671,489475,4,9,,103284327,1923,Unspecified,1703273.0,10988.0,,,Inhibition of human MetAP2 expressed in baculovirus infected Sf9 cells at 25 uM,Other,20621724.0,
672,489476,8,5,,103284327,1923,Active,1703273.0,10988.0,5.6,IC50,Inhibition of human MetAP2 expressed in baculovirus infected Sf9 cells,Confirmatory,20621724.0,
673,491968,3,4,,103284327,1923,Active,,,0.0029,IC50,Antioxidant activity against AAPH-induced peroxyl radicals assessed as trolox equivalents measured for 80 mins by ORAC-FL method,Confirmatory,20545360.0,
674,491969,3,3,,103284327,1923,Unspecified,,,,,Selectivity ratio of IC50 for bovine erythrocyte AChE to IC50 for human erythrocyte AChE,Other,20545360.0,
675,491973,9,2,,103284327,1923,Unspecified,116353.0,590.0,0.1,IC50,Inhibition of human serum BChE by Ellman's reaction,Confirmatory,20545360.0,
676,491974,9,2,,103284327,1923,Unspecified,113037.0,43.0,0.1,IC50,Inhibition of human erythrocyte AChE by Ellman's reaction,Confirmatory,20545360.0,
677,492947,1,1,,49826123,1923,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
678,492967,1,2,,99301845,1923,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
679,493014,1,1,,49826123,1923,Inconclusive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
680,493056,1,1,,26752756,1923,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
681,493056,1,1,,49826123,1923,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
682,493084,1,1,,26752756,1923,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
683,493084,1,1,,49826123,1923,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
684,493162,1,2,,99301845,1923,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
685,504327,1,1,,49826123,1923,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
686,504332,1,1,,49826123,1923,Inconclusive,168985070.0,,0.1413,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
687,504333,1,1,,49826123,1923,Active,6683500.0,29994.0,10.0,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
688,504339,1,1,,26752756,1923,Inconclusive,162330054.0,,22.3872,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
689,504406,1,1,,49826123,1923,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
690,504408,2,1,,49826123,1923,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
691,504444,1,1,,26752756,1923,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
692,504466,1,1,,49826123,1923,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
693,504467,1,1,,49826123,1923,Inconclusive,116283940.0,79915.0,25.9185,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
694,504648,1,1,,26752756,1923,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
695,504651,1,1,,26752756,1923,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
696,504651,1,1,,49826123,1923,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
697,504652,1,1,,26752756,1923,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
698,504652,1,1,,49826123,1923,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
699,504660,1,1,,26752756,1923,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
700,504660,1,1,,49826123,1923,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
701,504810,1,2,,49826123,1923,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
702,504812,1,2,,49826123,1923,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
703,504832,1,1,,49826123,1923,Inconclusive,,,18.526,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
704,504834,1,1,,49826123,1923,Inconclusive,,,0.4654,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
705,504842,1,1,,49826123,1923,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
706,504845,1,1,,26752756,1923,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
707,504847,1,1,,26752756,1923,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
708,504884,1,2,,99355760,1923,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
709,504891,1,1,,26752756,1923,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
710,537733,2,3,,103284327,1923,Inactive,,,,,Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u,Other,20739103.0,
711,537734,5,2,,103284327,1923,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay,Other,20739103.0,
712,537735,2,3,,103284327,1923,Inactive,,,,,Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u,Other,20739103.0,
713,537736,5,2,,103284327,1923,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay,Other,20739103.0,
714,540267,1,1,,26752756,1923,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
715,540275,1,1,,26752756,1923,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
716,540275,1,1,,49826123,1923,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
717,540277,1,1,,26752756,1923,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
718,540277,1,1,,49826123,1923,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
719,540295,1,1,,99355760,1923,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
720,540308,1,1,,99355760,1923,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
721,540317,1,1,,26752756,1923,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
722,540364,1,2,,99355760,1923,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
723,566699,3,7,,103284327,1923,Unspecified,6686057.0,,,,Inhibition of mushroom tyrosinase at 1 mM after 10 mins,Other,21189019.0,
724,566700,3,7,,103284327,1923,Unspecified,126407.0,240.0,,,Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay,Other,21189019.0,
725,566701,3,8,,103284327,1923,Unspecified,50402185.0,,,,Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay,Other,21189019.0,
726,566702,2,9,,103284327,1923,Unspecified,116852.0,4312.0,,,Inhibition of human recombinant MMP1 at 1 mM after 30 mins,Other,21189019.0,
727,566703,3,7,,103284327,1923,Unspecified,116856.0,4313.0,,,Inhibition of human recombinant MMP2 at 1 mM after 30 mins,Other,21189019.0,
728,566704,2,9,,103284327,1923,Unspecified,116857.0,4314.0,,,Inhibition of human recombinant MMP3 at 1 mM after 30 mins,Other,21189019.0,
729,566705,3,7,,103284327,1923,Unspecified,116862.0,4317.0,,,Inhibition of human recombinant MMP8 at 1 mM after 30 mins,Other,21189019.0,
730,566706,3,7,,103284327,1923,Unspecified,269849668.0,4318.0,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,Other,21189019.0,
731,566707,3,7,,103284327,1923,Unspecified,266649.0,18126.0,,,Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay,Other,21189019.0,
732,566708,7,5,,103284327,1923,Unspecified,116856.0,4313.0,130.0,IC50,Inhibition of human recombinant MMP2 after 30 mins,Confirmatory,21189019.0,
733,588335,1,1,,99355760,1923,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
734,588342,1,1,,49826123,1923,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
735,588352,1,2,,99355760,1923,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
736,588354,1,1,,99355760,1923,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
737,588405,1,1,,99355760,1923,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
738,588436,1,1,,99355760,1923,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
739,588453,1,1,,26752756,1923,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
740,588456,1,1,,26752756,1923,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
741,588458,1,1,,99355760,1923,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
742,588489,1,1,,99355760,1923,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
743,588492,1,1,,99355760,1923,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
744,588493,1,2,,99355760,1923,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
745,588497,1,2,,99355760,1923,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
746,588497,1,2,,99355760,1923,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
747,588497,1,2,,99355760,1923,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
748,588499,1,3,,99355760,1923,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
749,588499,1,3,,99355760,1923,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
750,588499,1,3,,99355760,1923,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
751,588501,1,2,,99355760,1923,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
752,588501,1,2,,99355760,1923,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
753,588501,1,2,,99355760,1923,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
754,588511,1,2,,49826123,1923,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
755,588513,1,1,,17389213,1923,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
756,588513,1,1,,17389852,1923,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
757,588514,1,1,,17389213,1923,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
758,588514,1,1,,17389852,1923,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
759,588515,1,1,,17389213,1923,Inconclusive,124375976.0,367.0,44.6684,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
760,588515,1,1,,17389852,1923,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
761,588516,1,1,,17389213,1923,Inconclusive,124375976.0,367.0,14.1254,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
762,588516,1,1,,17389852,1923,Inconclusive,124375976.0,367.0,28.1838,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
763,588526,1,1,,17389213,1923,Inconclusive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
764,588526,1,1,,17389852,1923,Inconclusive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
765,588527,1,1,,17389213,1923,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
766,588527,1,1,,17389852,1923,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
767,588532,1,1,,17389213,1923,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
768,588532,1,1,,17389852,1923,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
769,588533,1,1,,17389213,1923,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
770,588533,1,1,,17389852,1923,Inconclusive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
771,588534,1,1,,17389213,1923,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
772,588534,1,1,,17389852,1923,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
773,588535,1,1,,17389213,1923,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
774,588535,1,1,,17389852,1923,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
775,588536,1,1,,17389213,1923,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
776,588536,1,1,,17389852,1923,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
777,588537,1,1,,17389213,1923,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
778,588537,1,1,,17389852,1923,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
779,588541,1,1,,17389213,1923,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
780,588541,1,1,,17389852,1923,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
781,588543,1,1,,17389213,1923,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
782,588543,1,1,,17389852,1923,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
783,588544,1,1,,17389213,1923,Inconclusive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
784,588544,1,1,,17389852,1923,Inconclusive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
785,588545,1,1,,17389213,1923,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
786,588545,1,1,,17389852,1923,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
787,588546,1,1,,17389213,1923,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
788,588546,1,1,,17389852,1923,Inconclusive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
789,588547,1,1,,17389213,1923,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
790,588547,1,1,,17389852,1923,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
791,588549,1,1,,99355760,1923,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
792,588579,1,1,,26752756,1923,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
793,588590,1,1,,26752756,1923,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
794,588621,1,1,,99355760,1923,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
795,588627,1,1,,49826123,1923,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
796,588664,1,2,,99355760,1923,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
797,588664,1,2,,99355760,1923,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
798,588674,1,2,,99355760,1923,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
799,588675,1,1,,49826123,1923,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
800,588676,1,1,,49826123,1923,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
801,588692,2,1,,99355760,1923,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
802,588726,1,2,,99355760,1923,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
803,588795,1,1,,26752756,1923,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
804,588812,1,1,,17389213,1923,Unspecified,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
805,588812,1,1,,17389852,1923,Unspecified,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
806,588812,1,1,1.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
807,588812,1,1,1.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
808,588812,1,1,2.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
809,588812,1,1,2.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
810,588812,1,1,3.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
811,588812,1,1,3.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
812,588812,1,1,4.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
813,588812,1,1,4.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
814,588812,1,1,5.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
815,588812,1,1,5.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
816,588812,1,1,6.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
817,588812,1,1,6.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
818,588812,1,1,7.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
819,588812,1,1,7.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
820,588812,1,1,8.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
821,588812,1,1,8.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
822,588812,1,1,9.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
823,588812,1,1,9.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
824,588812,1,1,10.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
825,588812,1,1,10.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
826,588812,1,1,11.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
827,588812,1,1,11.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
828,588812,1,1,12.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
829,588812,1,1,12.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
830,588812,1,1,13.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
831,588812,1,1,13.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
832,588812,1,1,14.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
833,588812,1,1,14.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
834,588812,1,1,15.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
835,588812,1,1,15.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
836,588812,1,1,16.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
837,588812,1,1,16.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
838,588812,1,1,17.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
839,588812,1,1,17.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
840,588812,1,1,18.0,17389213,1923,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
841,588812,1,1,18.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
842,588812,1,1,19.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
843,588812,1,1,19.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
844,588812,1,1,20.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
845,588812,1,1,20.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
846,588812,1,1,21.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
847,588812,1,1,21.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
848,588812,1,1,22.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
849,588812,1,1,22.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
850,588812,1,1,23.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
851,588812,1,1,23.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
852,588812,1,1,24.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
853,588812,1,1,24.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
854,588812,1,1,25.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
855,588812,1,1,25.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
856,588812,1,1,26.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
857,588812,1,1,26.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
858,588812,1,1,27.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
859,588812,1,1,27.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
860,588812,1,1,28.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
861,588812,1,1,28.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
862,588812,1,1,29.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
863,588812,1,1,29.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
864,588812,1,1,30.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
865,588812,1,1,30.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
866,588812,1,1,31.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
867,588812,1,1,31.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
868,588812,1,1,32.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
869,588812,1,1,32.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
870,588812,1,1,33.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
871,588812,1,1,33.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
872,588812,1,1,34.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
873,588812,1,1,34.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
874,588812,1,1,35.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
875,588812,1,1,35.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
876,588812,1,1,36.0,17389213,1923,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
877,588812,1,1,36.0,17389852,1923,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
878,588812,1,1,37.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
879,588812,1,1,37.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
880,588812,1,1,38.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
881,588812,1,1,38.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
882,588812,1,1,39.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
883,588812,1,1,39.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
884,588812,1,1,40.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
885,588812,1,1,40.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
886,588812,1,1,41.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
887,588812,1,1,41.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
888,588812,1,1,42.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
889,588812,1,1,42.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
890,588812,1,1,43.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
891,588812,1,1,43.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
892,588812,1,1,44.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
893,588812,1,1,44.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
894,588812,1,1,45.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
895,588812,1,1,45.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
896,588812,1,1,46.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
897,588812,1,1,46.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
898,588812,1,1,47.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
899,588812,1,1,47.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
900,588812,1,1,48.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
901,588812,1,1,48.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
902,588812,1,1,49.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
903,588812,1,1,49.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
904,588812,1,1,50.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
905,588812,1,1,50.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
906,588812,1,1,51.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
907,588812,1,1,51.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
908,588812,1,1,52.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
909,588812,1,1,52.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
910,588812,1,1,53.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
911,588812,1,1,53.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
912,588812,1,1,54.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
913,588812,1,1,54.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
914,588812,1,1,55.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
915,588812,1,1,55.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
916,588812,1,1,56.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
917,588812,1,1,56.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
918,588812,1,1,57.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
919,588812,1,1,57.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
920,588812,1,1,58.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
921,588812,1,1,58.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
922,588812,1,1,59.0,17389213,1923,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
923,588812,1,1,59.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
924,588812,1,1,60.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
925,588812,1,1,60.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
926,588812,1,1,61.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
927,588812,1,1,61.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
928,588812,1,1,62.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
929,588812,1,1,62.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
930,588812,1,1,63.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
931,588812,1,1,63.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
932,588812,1,1,64.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
933,588812,1,1,64.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
934,588812,1,1,65.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
935,588812,1,1,65.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
936,588812,1,1,66.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
937,588812,1,1,66.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
938,588812,1,1,67.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
939,588812,1,1,67.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
940,588812,1,1,68.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
941,588812,1,1,68.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
942,588812,1,1,69.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
943,588812,1,1,69.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
944,588812,1,1,70.0,17389213,1923,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
945,588812,1,1,70.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
946,588812,1,1,71.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
947,588812,1,1,71.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
948,588812,1,1,72.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
949,588812,1,1,72.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
950,588812,1,1,73.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
951,588812,1,1,73.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
952,588812,1,1,74.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
953,588812,1,1,74.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
954,588812,1,1,75.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
955,588812,1,1,75.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
956,588812,1,1,76.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
957,588812,1,1,76.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
958,588812,1,1,77.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
959,588812,1,1,77.0,17389852,1923,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
960,588812,1,1,78.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
961,588812,1,1,78.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
962,588812,1,1,79.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
963,588812,1,1,79.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
964,588812,1,1,80.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
965,588812,1,1,80.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
966,588812,1,1,81.0,17389213,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
967,588812,1,1,81.0,17389852,1923,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
968,588813,1,1,,17389213,1923,Unspecified,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
969,588813,1,1,,17389852,1923,Unspecified,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
970,588813,1,1,1.0,17389213,1923,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
971,588813,1,1,1.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
972,588813,1,1,2.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
973,588813,1,1,2.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
974,588813,1,1,3.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
975,588813,1,1,3.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
976,588813,1,1,4.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
977,588813,1,1,4.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
978,588813,1,1,5.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
979,588813,1,1,5.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
980,588813,1,1,6.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
981,588813,1,1,6.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
982,588813,1,1,7.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
983,588813,1,1,7.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
984,588813,1,1,8.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
985,588813,1,1,8.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
986,588813,1,1,9.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
987,588813,1,1,9.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
988,588813,1,1,10.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
989,588813,1,1,10.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
990,588813,1,1,11.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
991,588813,1,1,11.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
992,588813,1,1,12.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
993,588813,1,1,12.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
994,588813,1,1,13.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
995,588813,1,1,13.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
996,588813,1,1,14.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
997,588813,1,1,14.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
998,588813,1,1,15.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
999,588813,1,1,15.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1000,588813,1,1,16.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1001,588813,1,1,16.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1002,588813,1,1,17.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1003,588813,1,1,17.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1004,588813,1,1,18.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1005,588813,1,1,18.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1006,588813,1,1,19.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1007,588813,1,1,19.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1008,588813,1,1,20.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1009,588813,1,1,20.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1010,588813,1,1,21.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1011,588813,1,1,21.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1012,588813,1,1,22.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1013,588813,1,1,22.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1014,588813,1,1,23.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1015,588813,1,1,23.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1016,588813,1,1,24.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1017,588813,1,1,24.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1018,588813,1,1,25.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1019,588813,1,1,25.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1020,588813,1,1,26.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1021,588813,1,1,26.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1022,588813,1,1,27.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1023,588813,1,1,27.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1024,588813,1,1,28.0,17389213,1923,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1025,588813,1,1,28.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1026,588813,1,1,29.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1027,588813,1,1,29.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1028,588813,1,1,30.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1029,588813,1,1,30.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1030,588813,1,1,31.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1031,588813,1,1,31.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1032,588813,1,1,32.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1033,588813,1,1,32.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1034,588813,1,1,33.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1035,588813,1,1,33.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1036,588813,1,1,34.0,17389213,1923,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1037,588813,1,1,34.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1038,588813,1,1,35.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1039,588813,1,1,35.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1040,588813,1,1,36.0,17389213,1923,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1041,588813,1,1,36.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1042,588813,1,1,37.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1043,588813,1,1,37.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1044,588813,1,1,38.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1045,588813,1,1,38.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1046,588813,1,1,39.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1047,588813,1,1,39.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1048,588813,1,1,40.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1049,588813,1,1,40.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1050,588813,1,1,41.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1051,588813,1,1,41.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1052,588813,1,1,42.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1053,588813,1,1,42.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1054,588813,1,1,43.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1055,588813,1,1,43.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1056,588813,1,1,44.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1057,588813,1,1,44.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1058,588813,1,1,45.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1059,588813,1,1,45.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1060,588813,1,1,46.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1061,588813,1,1,46.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1062,588813,1,1,47.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1063,588813,1,1,47.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1064,588813,1,1,48.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1065,588813,1,1,48.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1066,588813,1,1,49.0,17389213,1923,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1067,588813,1,1,49.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1068,588813,1,1,50.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1069,588813,1,1,50.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1070,588813,1,1,51.0,17389213,1923,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1071,588813,1,1,51.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1072,588813,1,1,52.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1073,588813,1,1,52.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1074,588813,1,1,53.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1075,588813,1,1,53.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1076,588813,1,1,54.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1077,588813,1,1,54.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1078,588813,1,1,55.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1079,588813,1,1,55.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1080,588813,1,1,56.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1081,588813,1,1,56.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1082,588813,1,1,57.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1083,588813,1,1,57.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1084,588813,1,1,58.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1085,588813,1,1,58.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1086,588813,1,1,59.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1087,588813,1,1,59.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1088,588813,1,1,60.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1089,588813,1,1,60.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1090,588813,1,1,61.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1091,588813,1,1,61.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1092,588813,1,1,62.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1093,588813,1,1,62.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1094,588813,1,1,63.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1095,588813,1,1,63.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1096,588813,1,1,64.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1097,588813,1,1,64.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1098,588813,1,1,65.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1099,588813,1,1,65.0,17389852,1923,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1100,588813,1,1,66.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1101,588813,1,1,66.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1102,588813,1,1,67.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1103,588813,1,1,67.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1104,588813,1,1,68.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1105,588813,1,1,68.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1106,588813,1,1,69.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1107,588813,1,1,69.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1108,588813,1,1,70.0,17389213,1923,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1109,588813,1,1,70.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1110,588813,1,1,71.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1111,588813,1,1,71.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1112,588813,1,1,72.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1113,588813,1,1,72.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1114,588813,1,1,73.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1115,588813,1,1,73.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1116,588813,1,1,74.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1117,588813,1,1,74.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1118,588813,1,1,75.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1119,588813,1,1,75.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1120,588813,1,1,76.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1121,588813,1,1,76.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1122,588813,1,1,77.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1123,588813,1,1,77.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1124,588813,1,1,78.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1125,588813,1,1,78.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1126,588813,1,1,79.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1127,588813,1,1,79.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1128,588813,1,1,80.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1129,588813,1,1,80.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1130,588813,1,1,81.0,17389213,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1131,588813,1,1,81.0,17389852,1923,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1132,588814,1,3,,99355760,1923,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
1133,588819,1,4,,99355760,1923,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
1134,588832,1,1,,99355760,1923,Inactive,7300964.0,,,,Hedgehog Measured in Biochemical System Using Plate Reader - 2070-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1135,588834,2,1,,17389213,1923,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1136,588834,2,1,,17389852,1923,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1137,588850,1,1,,99355760,1923,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
1138,588852,1,3,,99355760,1923,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
1139,588855,1,1,,26752756,1923,Active,18418623.0,4088.0,3.5481,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
1140,588856,1,1,,26752756,1923,Active,,,5.6234,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
1141,589073,1,10,,103284327,1923,Unspecified,29839637.0,54576.0,,,Substrate of human UDP-glucuronosyltransferase UGT1A8,Other,,
1142,602123,1,1,,99355760,1923,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
1143,602141,1,1,,99355760,1923,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
1144,602162,1,1,,99355760,1923,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
1145,602163,1,1,,99355760,1923,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
1146,602229,1,1,,99355760,1923,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1147,602244,1,2,,99355760,1923,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
1148,602247,1,2,,99355760,1923,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1149,602248,1,2,,99355760,1923,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1150,602250,1,2,,99355760,1923,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
1151,602261,1,1,,99355760,1923,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
1152,602274,1,2,,99355760,1923,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
1153,602281,1,1,,99355760,1923,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1154,602281,1,1,,99355760,1923,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1155,602310,1,2,,26752756,1923,Inconclusive,13399304.0,60489.0,6.3096,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1156,602329,1,1,,99355760,1923,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1157,602332,1,1,,26752756,1923,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1158,602332,1,1,,124889868,1923,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1159,602340,1,2,,99355760,1923,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
1160,602342,2,1,,99355760,1923,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1161,602346,1,1,,99355760,1923,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1162,602363,1,1,,99355760,1923,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
1163,602393,1,1,,99355760,1923,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1164,602396,1,2,,99355760,1923,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1165,602399,1,2,,99355760,1923,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
1166,602405,1,1,,99355760,1923,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1167,602429,1,1,,99355760,1923,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
1168,602438,1,1,,99355760,1923,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
1169,602440,1,1,,99355760,1923,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1170,602449,1,2,,99355760,1923,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1171,602481,1,1,,99355760,1923,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1172,623901,1,1,,99355760,1923,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1173,624030,1,2,,26752756,1923,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
1174,624030,1,2,,124889868,1923,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
1175,624037,1,3,,99355760,1923,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1176,624038,1,3,,99355760,1923,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1177,624040,1,3,,99355760,1923,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1178,624125,1,4,,99355760,1923,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1179,624126,1,3,,99355760,1923,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1180,624127,1,2,,99355760,1923,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1181,624156,1,1,,85789208,1923,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1182,624168,1,1,,99355760,1923,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1183,624169,1,1,,99355760,1923,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1184,624170,1,1,,26752756,1923,Inconclusive,71051501.0,2744.0,28.1838,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1185,624170,1,1,,124889868,1923,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1186,624172,1,1,,26752756,1923,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1187,624172,1,1,,124889868,1923,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1188,624173,1,3,,26752756,1923,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1189,624173,1,3,,124889868,1923,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1190,624178,1,1,,26752756,1923,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1191,624202,1,1,,26752756,1923,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1192,624204,1,2,,99355760,1923,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1193,624256,1,2,,99355760,1923,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1194,624263,1,1,,26752756,1923,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1195,624263,1,1,,26752756,1923,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1196,624267,1,2,,99355760,1923,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1197,624267,1,2,,99355760,1923,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1198,624268,1,3,,99355760,1923,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1199,624304,1,2,,99355760,1923,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1200,624352,1,1,,99355760,1923,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1201,624354,1,1,,99355760,1923,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1202,624377,1,1,,99355760,1923,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1203,624414,1,1,,26752756,1923,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1204,624415,1,2,,26752756,1923,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1205,624416,1,1,,99355760,1923,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1206,624466,1,3,,99355760,1923,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1207,624467,1,1,,99355760,1923,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1208,624483,1,1,,99355760,1923,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1209,624616,1,8,,103284327,1923,Unspecified,332278237.0,7366.0,,,Specific activity of expressed human recombinant UGT2B15,Other,10836148.0,
1210,625144,5,5,,103284327,1923,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1211,625145,4,7,,103284327,1923,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1212,625146,5,5,,103284327,1923,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1213,625147,4,7,,103284327,1923,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1214,625148,4,7,,103284327,1923,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1215,625149,4,7,,103284327,1923,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1216,625150,5,5,,103284327,1923,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1217,625151,4,7,,103284327,1923,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1218,625152,4,7,,103284327,1923,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1219,625153,4,7,,103284327,1923,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1220,625154,4,7,,103284327,1923,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1221,625155,4,7,,103284327,1923,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1222,625156,1,9,,103284327,1923,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1223,625157,6,2,,103284327,1923,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1224,625158,3,4,,103284327,1923,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1225,625159,5,5,,103284327,1923,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1226,625160,1,9,,103284327,1923,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1227,625161,4,7,,103284327,1923,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1228,625162,4,7,,103284327,1923,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1229,625163,4,7,,103284327,1923,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1230,625164,1,6,,103284327,1923,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1231,625165,3,4,,103284327,1923,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1232,625166,3,4,,103284327,1923,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1233,625167,5,5,,103284327,1923,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1234,625168,4,7,,103284327,1923,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1235,625169,1,6,,103284327,1923,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1236,625170,3,4,,103284327,1923,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1237,625171,4,7,,103284327,1923,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1238,625172,4,7,,103284327,1923,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1239,625173,5,5,,103284327,1923,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1240,625174,5,5,,103284327,1923,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1241,625175,5,5,,103284327,1923,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1242,625176,1,9,,103284327,1923,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1243,625177,5,5,,103284327,1923,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1244,625178,5,5,,103284327,1923,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1245,625179,1,9,,103284327,1923,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1246,625180,5,5,,103284327,1923,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1247,625181,5,5,,103284327,1923,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1248,625182,5,5,,103284327,1923,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1249,625183,5,5,,103284327,1923,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1250,625184,5,5,,103284327,1923,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1251,625185,5,5,,103284327,1923,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1252,625186,5,5,,103284327,1923,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1253,625187,5,5,,103284327,1923,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1254,625188,1,9,,103284327,1923,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1255,625189,1,7,,103284327,1923,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1256,625190,4,5,,103284327,1923,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1257,625191,4,7,,103284327,1923,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1258,625192,4,7,,103284327,1923,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1259,625193,5,5,,103284327,1923,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1260,625194,4,7,,103284327,1923,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1261,625195,4,7,,103284327,1923,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1262,625196,5,6,,103284327,1923,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1263,625197,3,4,,103284327,1923,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1264,625198,4,7,,103284327,1923,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1265,625199,4,7,,103284327,1923,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1266,625200,4,7,,103284327,1923,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1267,625201,4,7,,103284327,1923,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1268,625202,4,7,,103284327,1923,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1269,625203,4,7,,103284327,1923,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1270,625204,4,7,,103284327,1923,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1271,625205,4,7,,103284327,1923,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1272,625206,4,7,,103284327,1923,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1273,625207,4,7,,103284327,1923,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1274,625208,5,5,,103284327,1923,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
1275,625209,4,7,,103284327,1923,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
1276,625210,3,4,,103284327,1923,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
1277,625211,1,6,,103284327,1923,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
1278,625212,3,4,,103284327,1923,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
1279,625213,4,7,,103284327,1923,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
1280,625214,1,9,,103284327,1923,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
1281,625215,3,4,,103284327,1923,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
1282,625216,3,4,,103284327,1923,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
1283,625217,4,7,,103284327,1923,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1284,625218,4,7,,103284327,1923,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1285,625219,3,4,,103284327,1923,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1286,625220,4,7,,103284327,1923,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1287,625221,4,7,,103284327,1923,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1288,625222,4,7,,103284327,1923,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1289,625223,4,7,,103284327,1923,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1290,625224,3,4,,103284327,1923,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1291,625225,3,4,,103284327,1923,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1292,625226,4,7,,103284327,1923,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1293,625227,4,7,,103284327,1923,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1294,625228,4,7,,103284327,1923,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1295,625229,5,5,,103284327,1923,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1296,625230,1,6,,103284327,1923,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1297,625231,4,7,,103284327,1923,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1298,625232,1,9,,103284327,1923,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1299,625233,4,7,,103284327,1923,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1300,625234,3,4,,103284327,1923,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1301,625235,4,7,,103284327,1923,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1302,625236,5,5,,103284327,1923,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1303,625237,4,7,,103284327,1923,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1304,625238,4,7,,103284327,1923,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1305,625239,4,7,,103284327,1923,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1306,625240,1,9,,103284327,1923,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1307,625241,4,7,,103284327,1923,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1308,625242,4,7,,103284327,1923,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1309,625243,5,5,,103284327,1923,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1310,625244,5,5,,103284327,1923,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1311,625245,5,5,,103284327,1923,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1312,625246,1,9,,103284327,1923,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1313,625247,5,5,,103284327,1923,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1314,625248,5,5,,103284327,1923,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1315,625249,5,5,,103284327,1923,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1316,625250,5,5,,103284327,1923,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1317,625251,5,5,,103284327,1923,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1318,625252,4,7,,103284327,1923,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1319,625253,4,7,,103284327,1923,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1320,625254,4,7,,103284327,1923,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1321,625255,4,7,,103284327,1923,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1322,625256,4,7,,103284327,1923,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1323,625257,4,7,,103284327,1923,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1324,625258,4,7,,103284327,1923,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1325,625259,4,7,,103284327,1923,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1326,625260,3,4,,103284327,1923,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1327,625261,3,4,,103284327,1923,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1328,625262,3,4,,103284327,1923,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1329,625263,4,7,,103284327,1923,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1330,625264,3,4,,103284327,1923,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1331,625265,1,6,,103284327,1923,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1332,625266,3,4,,103284327,1923,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1333,625267,3,4,,103284327,1923,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1334,625268,4,2,,103284327,1923,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1335,625268,4,2,,103284327,1923,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1336,625268,4,2,,103284327,1923,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1337,625268,4,2,,103284327,1923,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1338,625269,4,7,,103284327,1923,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1339,625270,4,7,,103284327,1923,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1340,625271,5,5,,103284327,1923,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1341,625272,3,4,,103284327,1923,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1342,625273,4,6,,103284327,1923,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1343,625274,1,6,,103284327,1923,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1344,625275,3,4,,103284327,1923,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1345,637433,1,5,,103284327,1923,Unspecified,,,,,Antioxidant activity assessed as trolox equivalents ratio of AAPH-induced peroxyl radical scavenging activity at 0.01 mM by ORAC assay,Other,22197671.0,
1346,637434,1,5,,103284327,1923,Unspecified,,,,,Antioxidant activity assessed as trolox equivalents ratio of AAPH-induced peroxyl radical scavenging activity at 0.001 mM by ORAC assay,Other,22197671.0,
1347,637435,1,5,,103284327,1923,Unspecified,,,,,Antioxidant activity assessed as trolox equivalents ratio of AAPH-induced peroxyl radical scavenging activity at 0.1 mM by ORAC assay,Other,22197671.0,
1348,637436,1,5,,103284327,1923,Inactive,,,,,Antioxidant activity assessed as AAPH-induced peroxyl radical scavenging activity at 1 mM by ORAC assay,Other,22197671.0,
1349,637437,1,4,,103284327,1923,Unspecified,,,,,Antioxidant activity assessed as trolox equivalents ratio of ferric ion reducing activity using fe3+-TPTZ at 0.001 mM by FRAP assay,Other,22197671.0,
1350,637438,1,4,,103284327,1923,Unspecified,,,,,Antioxidant activity assessed as trolox equivalents ratio of ferric ion reducing activity using fe3+-TPTZ at 0.01 mM by FRAP assay,Other,22197671.0,
1351,637439,1,4,,103284327,1923,Unspecified,,,,,Antioxidant activity assessed as trolox equivalents ratio of ferric ion reducing activity using fe3+-TPTZ at 0.1 mM by FRAP assay,Other,22197671.0,
1352,637440,1,4,,103284327,1923,Inactive,,,,,Antioxidant activity assessed as ferric ion reducing activity using fe3+-TPTZ at 1 mM by FRAP assay,Other,22197671.0,
1353,637441,1,4,,103284327,1923,Inactive,,,,,Antioxidant activity against toxin solution-induced lipid peroxidation in Sprague-Dawley rat brain homogenates assessed as free MDA levels per mg of tissue at 0.001 by TBARS assay (Rvb = 0.93 +/- 0.09 nmol),Other,22197671.0,
1354,637442,1,4,,103284327,1923,Unspecified,,,,,Antioxidant activity against toxin solution-induced lipid peroxidation in Sprague-Dawley rat brain homogenates assessed as free MDA levels per mg of tissue at 0.01 by TBARS assay (Rvb = 0.93 +/- 0.09 nmol),Other,22197671.0,
1355,637443,1,4,,103284327,1923,Unspecified,,,,,Antioxidant activity against toxin solution-induced lipid peroxidation in Sprague-Dawley rat brain homogenates assessed as free MDA levels per mg of tissue at 0.1 by TBARS assay (Rvb = 0.93 +/- 0.09 nmol),Other,22197671.0,
1356,637444,1,4,,103284327,1923,Unspecified,,,,,Antioxidant activity against toxin solution-induced lipid peroxidation in Sprague-Dawley rat brain homogenates assessed as free MDA levels per mg of tissue at 1 by TBARS assay (Rvb = 0.93 +/- 0.09 nmol),Other,22197671.0,
1357,643059,4,5,,103284327,1923,Unspecified,2497687.0,7941.0,100.0,IC50,Inhibition of human plasma lipoprotein-associated phospholipase A2 using 2-thio-PAF as substrate preincubated for 20 mins measured 1 hr post substrate addition by spectrophotometric analysis,Confirmatory,22217870.0,
1358,643060,4,5,,103284327,1923,Unspecified,2497687.0,7941.0,100.0,IC50,Inhibition of human plasma lipoprotein-associated phospholipase A2 using 2-thio-PAF as substrate preincubated for 20 mins measured 1 hr post substrate addition by spectrophotometric analysis in presence of EDTA,Confirmatory,22217870.0,
1359,651560,1,1,,99355760,1923,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1360,651572,1,2,,99355760,1923,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1361,651602,1,1,,99355760,1923,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1362,651602,1,1,,99355760,1923,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1363,651602,1,1,,99355760,1923,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1364,651631,4,1,,144206634,1923,Active,269849759.0,7157.0,23.7101,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1365,651631,4,1,,144210184,1923,Active,269849759.0,7157.0,13.755,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1366,651631,4,1,,144213967,1923,Active,269849759.0,7157.0,15.3553,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1367,651632,4,1,,144206634,1923,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1368,651632,4,1,,144210184,1923,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1369,651632,4,1,,144213967,1923,Inactive,296439460.0,79915.0,68.5896,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1370,651633,4,1,,144206634,1923,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1371,651633,4,1,,144210184,1923,Active,,,21.8003,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1372,651633,4,1,,144213967,1923,Active,,,21.6899,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1373,651634,4,1,,144206634,1923,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1374,651634,4,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1375,651634,4,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1376,651636,1,1,,99355760,1923,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1377,651640,1,1,,99355760,1923,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1378,651647,1,1,,99355760,1923,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1379,651654,1,1,,99355760,1923,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1380,651658,1,1,,99355760,1923,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1381,651661,2,1,,99355760,1923,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1382,651687,1,1,,99355760,1923,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1383,651699,1,1,,99355760,1923,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1384,651699,1,1,,99355760,1923,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1385,651702,1,2,,99355760,1923,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1386,651704,2,1,,99355760,1923,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1387,651710,1,1,,99355760,1923,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1388,651711,2,1,,99355760,1923,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1389,651718,1,2,,99355760,1923,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1390,651719,1,2,,99355760,1923,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
1391,651723,1,1,,99355760,1923,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
1392,651741,1,1,,17389213,1923,Active,20149576.0,4780.0,37.578,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1393,651741,1,1,,17389852,1923,Active,20149576.0,4780.0,66.8242,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1394,651743,1,1,,17389213,1923,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1395,651743,1,1,,17389852,1923,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1396,651749,1,1,,17389213,1923,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1397,651749,1,1,,17389852,1923,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1398,651751,1,1,,17389213,1923,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1399,651751,1,1,,17389852,1923,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1400,651754,1,1,,17389213,1923,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
1401,651754,1,1,,17389852,1923,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
1402,651755,1,1,,17389213,1923,Inconclusive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
1403,651755,1,1,,17389852,1923,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
1404,651757,1,1,,17389213,1923,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
1405,651757,1,1,,17389852,1923,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
1406,651758,1,1,,17389213,1923,Inconclusive,186368.0,3576.0,59.5572,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
1407,651758,1,1,,17389852,1923,Inactive,186368.0,3576.0,,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
1408,651777,1,1,,17389213,1923,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1409,651777,1,1,,17389852,1923,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1410,651778,1,1,,17389213,1923,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1411,651778,1,1,,17389852,1923,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1412,651800,1,1,,99355760,1923,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1413,651802,1,1,,17389213,1923,Inactive,49066040.0,6097.0,,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1414,651802,1,1,,17389852,1923,Active,49066040.0,6097.0,3.3491,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1415,651821,2,4,,99355760,1923,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1416,651838,1,1,,17389213,1923,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1417,651838,1,1,,17389852,1923,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1418,651838,1,1,1.0,17389213,1923,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1419,651838,1,1,1.0,17389852,1923,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1420,651838,1,1,2.0,17389213,1923,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1421,651838,1,1,2.0,17389852,1923,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1422,651838,1,1,3.0,17389213,1923,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1423,651838,1,1,3.0,17389852,1923,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1424,651838,1,1,4.0,17389213,1923,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1425,651838,1,1,4.0,17389852,1923,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1426,651838,1,1,5.0,17389213,1923,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1427,651838,1,1,5.0,17389852,1923,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1428,651838,1,1,6.0,17389213,1923,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1429,651838,1,1,6.0,17389852,1923,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1430,651838,1,1,7.0,17389213,1923,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1431,651838,1,1,7.0,17389852,1923,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1432,651838,1,1,8.0,17389213,1923,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1433,651838,1,1,8.0,17389852,1923,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1434,651957,1,1,,99355760,1923,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1435,651958,1,1,,99355760,1923,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1436,651999,1,1,,99355760,1923,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1437,652010,1,1,,99355760,1923,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
1438,652017,1,1,,99355760,1923,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
1439,652039,1,1,,99355760,1923,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
1440,652048,1,2,,144206634,1923,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1441,652048,1,2,,144213967,1923,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1442,652051,1,1,,144206634,1923,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1443,652051,1,1,,144213967,1923,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1444,652067,1,4,,99355760,1923,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
1445,652106,1,1,,144206634,1923,Inconclusive,586067.0,6622.0,25.1189,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1446,652115,1,1,,99355760,1923,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
1447,652126,1,3,,99355760,1923,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
1448,652162,2,1,,99355760,1923,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1449,652163,1,1,,99355760,1923,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1450,652197,1,1,,99355760,1923,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1451,652257,1,1,,99355760,1923,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
1452,686940,1,1,,99355760,1923,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1453,686964,1,1,,99355760,1923,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1454,686978,1,1,,144206634,1923,Active,79154014.0,55775.0,4.7318,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1455,686978,1,1,,144213967,1923,Active,79154014.0,55775.0,9.6885,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1456,686979,1,1,,144206634,1923,Active,79154014.0,55775.0,5.3091,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1457,686979,1,1,,144213967,1923,Active,79154014.0,55775.0,6.859,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1458,686996,1,1,,99355760,1923,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1459,687014,1,1,,99355760,1923,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1460,687016,1,1,,99355760,1923,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1461,694802,1,7,,103284327,1923,Inactive,399133.0,,,,Inhibition of Clostridium botulinum neurotoxin serotype A light chain at 500 uM,Other,20959871.0,
1462,694803,2,7,,103284327,1923,Inactive,399133.0,,,IC50,Inhibition of Clostridium botulinum neurotoxin serotype A light chain preincubated for 5 mins before SNAPtid substrate addition by FRET assay,Confirmatory,20959871.0,
1463,720508,1,1,,99355760,1923,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1464,720509,1,1,,99355760,1923,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1465,720511,1,1,,99355760,1923,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1466,720516,2,1,,144206634,1923,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1467,720516,2,1,,144210184,1923,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1468,720516,2,1,,144213967,1923,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1469,720532,1,1,,144206634,1923,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1470,720532,1,1,,144213967,1923,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1471,720533,1,1,,144206634,1923,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1472,720533,1,1,,144213967,1923,Inconclusive,,,44.6684,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1473,720543,1,1,,99355760,1923,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1474,720552,2,1,,144206634,1923,Active,269849759.0,7157.0,23.7101,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1475,720552,2,1,,144210184,1923,Active,269849759.0,7157.0,20.1896,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1476,720552,2,1,,144213967,1923,Inconclusive,269849759.0,7157.0,35.0818,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1477,720582,1,1,,99355760,1923,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1478,720596,1,1,,99355760,1923,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1479,720634,2,1,,144206634,1923,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1480,720634,2,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1481,720634,2,1,,144213967,1923,Inactive,,,43.2771,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1482,720635,2,1,,144206634,1923,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1483,720635,2,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1484,720635,2,1,,144213967,1923,Active,,,5.4483,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1485,720636,1,1,,17389213,1923,Inconclusive,20149576.0,4780.0,37.578,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
1486,720636,1,1,,17389852,1923,Active,20149576.0,4780.0,42.1632,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
1487,720637,2,1,,144206634,1923,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1488,720637,2,1,,144210184,1923,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1489,720637,2,1,,144213967,1923,Inconclusive,,,15.6528,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1490,720648,1,1,,99355760,1923,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1491,720652,1,1,,17389213,1923,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1492,720652,1,1,,17389852,1923,Inconclusive,,,42.1632,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1493,720653,1,1,,17389213,1923,Inconclusive,,,50.1187,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
1494,720653,1,1,,17389852,1923,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
1495,720659,1,1,,17389213,1923,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
1496,720659,1,1,,17389852,1923,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
1497,720674,2,2,,144206634,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1498,720674,2,2,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1499,720674,2,2,,144213967,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1500,720675,2,2,,144206634,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1501,720675,2,2,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1502,720675,2,2,,144213967,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1503,720678,2,1,,144206634,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1504,720678,2,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1505,720678,2,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1506,720679,2,1,,144206634,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1507,720679,2,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1508,720679,2,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1509,720680,2,1,,144206634,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1510,720680,2,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1511,720680,2,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1512,720681,2,1,,144206634,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1513,720681,2,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1514,720681,2,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1515,720682,2,1,,144206634,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1516,720682,2,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1517,720682,2,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1518,720683,2,1,,144206634,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1519,720683,2,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1520,720683,2,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1521,720684,2,1,,144206634,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1522,720684,2,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1523,720684,2,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1524,720685,2,1,,144206634,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1525,720685,2,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1526,720685,2,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1527,720686,2,1,,144206634,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1528,720686,2,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1529,720686,2,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1530,720687,2,2,,144206634,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1531,720687,2,2,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1532,720687,2,2,,144213967,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1533,720691,4,1,,144206634,1923,Active,311348376.0,2908.0,11.9856,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1534,720691,4,1,,144210184,1923,Active,311348376.0,2908.0,21.9929,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1535,720691,4,1,,144213967,1923,Active,311348376.0,2908.0,3.0896,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1536,720692,3,1,,144206634,1923,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1537,720692,3,1,,144210184,1923,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1538,720692,3,1,,144213967,1923,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1539,720693,3,1,,144206634,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1540,720693,3,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1541,720693,3,1,,144213967,1923,Inconclusive,,,38.8952,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1542,720700,1,4,,99355760,1923,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
1543,720702,1,1,,99355760,1923,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
1544,720704,1,4,,99355760,1923,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
1545,720719,2,1,,144206634,1923,Active,311348376.0,2908.0,11.1001,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1546,720719,2,1,,144210184,1923,Active,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1547,720719,2,1,,144213967,1923,Active,311348376.0,2908.0,15.2057,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1548,720725,2,1,,144206634,1923,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1549,720725,2,1,,144210184,1923,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1550,720725,2,1,,144213967,1923,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1551,727213,1,3,,103284327,1923,Unspecified,,,,,Cytotoxicity against human K562 cells at 50 ug/ml after 48 hrs by MTS assay relative to control,Other,24900641.0,
1552,727214,1,3,,103284327,1923,Unspecified,,,,,Cytotoxicity against human T47D cells at 50 ug/ml after 48 hrs by MTS assay relative to control,Other,24900641.0,
1553,743012,3,1,,144206634,1923,Active,,,2.1132,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1554,743012,3,1,,144210184,1923,Active,,,3.0794,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1555,743012,3,1,,144213967,1923,Active,,,0.2169,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1556,743014,3,1,,144206634,1923,Active,,,2.6603,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1557,743014,3,1,,144210184,1923,Active,,,1.943,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1558,743014,3,1,,144213967,1923,Active,,,0.2731,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1559,743015,3,1,,144206634,1923,Active,,,2.9849,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1560,743015,3,1,,144210184,1923,Active,,,2.4459999999999997,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1561,743015,3,1,,144213967,1923,Active,,,0.2169,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1562,743033,3,1,,144206634,1923,Active,,,6.74,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1563,743033,3,1,,144210184,1923,Active,,,0.6955,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1564,743033,3,1,,144213967,1923,Active,,,0.4365,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1565,743035,2,1,,144206634,1923,Inconclusive,124375976.0,367.0,15.089,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1566,743035,2,1,,144210184,1923,Inconclusive,124375976.0,367.0,5.5244,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1567,743035,2,1,,144213967,1923,Inconclusive,124375976.0,367.0,2.7536,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1568,743036,2,1,,144206634,1923,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1569,743036,2,1,,144210184,1923,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1570,743036,2,1,,144213967,1923,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1571,743040,3,1,,144206634,1923,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1572,743040,3,1,,144210184,1923,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1573,743040,3,1,,144213967,1923,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1574,743041,3,1,,144206634,1923,Active,,,6.6824,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1575,743041,3,1,,144210184,1923,Active,,,6.1442,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1576,743041,3,1,,144213967,1923,Active,,,3.0638,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1577,743042,3,1,,144206634,1923,Active,124375976.0,367.0,4.2163,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1578,743042,3,1,,144210184,1923,Active,124375976.0,367.0,2.7445,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1579,743042,3,1,,144213967,1923,Active,124375976.0,367.0,2.169,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1580,743053,2,1,,144206634,1923,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1581,743053,2,1,,144210184,1923,Inconclusive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1582,743053,2,1,,144213967,1923,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1583,743054,2,1,,144206634,1923,Inconclusive,124375976.0,367.0,15.5454,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1584,743054,2,1,,144210184,1923,Inconclusive,124375976.0,367.0,6.14415,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1585,743054,2,1,,144213967,1923,Inconclusive,124375976.0,367.0,10.1451,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1586,743063,2,1,,144206634,1923,Inconclusive,124375976.0,367.0,16.9301,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1587,743063,2,1,,144210184,1923,Inconclusive,124375976.0,367.0,1.4983600000000001,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1588,743063,2,1,,144213967,1923,Inconclusive,124375976.0,367.0,1.17672,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1589,743064,3,1,,144206634,1923,Active,,,2.9849,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1590,743064,3,1,,144210184,1923,Active,,,3.0794,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1591,743064,3,1,,144213967,1923,Active,,,2.4337,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1592,743065,3,1,,144206634,1923,Active,399498506.0,24831.0,2.9849,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1593,743065,3,1,,144210184,1923,Active,399498506.0,24831.0,3.0794,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1594,743065,3,1,,144213967,1923,Active,399498506.0,24831.0,2.4337,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1595,743066,3,1,,144206634,1923,Inconclusive,399498506.0,24831.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1596,743066,3,1,,144210184,1923,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1597,743066,3,1,,144213967,1923,Inactive,399498506.0,24831.0,2.4337,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1598,743067,2,1,,144206634,1923,Inconclusive,399498506.0,24831.0,3.22305,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1599,743067,2,1,,144210184,1923,Inconclusive,399498506.0,24831.0,3.07937,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1600,743067,2,1,,144213967,1923,Inconclusive,399498506.0,24831.0,3.8570800000000003,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1601,743069,2,1,,144206634,1923,Inconclusive,348019627.0,2099.0,10.6822,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1602,743069,2,1,,144210184,1923,Inactive,348019627.0,2099.0,55.2436,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1603,743069,2,1,,144213967,1923,Inconclusive,348019627.0,2099.0,1.3802,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1604,743074,2,1,,144206634,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1605,743074,2,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1606,743074,2,1,,144213967,1923,Inconclusive,,,4.3641,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1607,743075,2,1,,144206634,1923,Inconclusive,348019627.0,2099.0,26.8062,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1608,743075,2,1,,144210184,1923,Inconclusive,348019627.0,2099.0,2.4676,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1609,743075,2,1,,144213967,1923,Inconclusive,348019627.0,2099.0,19.4938,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1610,743077,2,1,,144206634,1923,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1611,743077,2,1,,144210184,1923,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1612,743077,2,1,,144213967,1923,Inconclusive,348019627.0,2099.0,43.6519,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1613,743078,2,1,,144206634,1923,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1614,743078,2,1,,144210184,1923,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1615,743078,2,1,,144213967,1923,Inconclusive,348019627.0,2099.0,23.1698,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1616,743079,3,1,,144206634,1923,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1617,743079,3,1,,144210184,1923,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1618,743079,3,1,,144213967,1923,Inactive,348019627.0,2099.0,17.2289,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1619,743080,3,1,,144206634,1923,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1620,743080,3,1,,144210184,1923,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1621,743080,3,1,,144213967,1923,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1622,743081,3,1,,144206634,1923,Inconclusive,,,18.8336,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1623,743081,3,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1624,743081,3,1,,144213967,1923,Inconclusive,,,27.305999999999997,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1625,743083,3,1,,144206634,1923,Active,119597822.0,1588.0,18.8336,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1626,743083,3,1,,144210184,1923,Active,119597822.0,1588.0,0.9738,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1627,743083,3,1,,144213967,1923,Active,119597822.0,1588.0,0.5448,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1628,743084,3,1,,144206634,1923,Inconclusive,,,11.8832,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1629,743084,3,1,,144210184,1923,Active,,,1.3755,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1630,743084,3,1,,144213967,1923,Active,,,0.6859,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1631,743085,3,1,,144206634,1923,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1632,743085,3,1,,144210184,1923,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1633,743085,3,1,,144213967,1923,Inactive,51095037.0,196.0,19.3312,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1634,743086,3,1,,144206634,1923,Active,,,18.8336,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1635,743086,3,1,,144210184,1923,Inconclusive,,,1.7317,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1636,743086,3,1,,144213967,1923,Active,,,0.6859,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1637,743091,2,1,,144206634,1923,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1638,743091,2,1,,144210184,1923,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1639,743091,2,1,,144213967,1923,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1640,743094,3,1,,144206634,1923,Inconclusive,216409692.0,5468.0,33.7801,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1641,743094,3,1,,144210184,1923,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1642,743094,3,1,,144213967,1923,Inconclusive,216409692.0,5468.0,1.23,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1643,743122,2,1,,144206634,1923,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1644,743122,2,1,,144210184,1923,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1645,743122,2,1,,144213967,1923,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1646,743126,1,1,,99355760,1923,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
1647,743139,2,1,,144206634,1923,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1648,743139,2,1,,144210184,1923,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1649,743139,2,1,,144213967,1923,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1650,743140,2,1,,144206634,1923,Active,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1651,743140,2,1,,144210184,1923,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1652,743140,2,1,,144213967,1923,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1653,743191,3,1,,144210184,1923,Inconclusive,216409692.0,5468.0,24.6764,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1654,743191,3,1,,144213967,1923,Inconclusive,216409692.0,5468.0,48.9662,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1655,743194,3,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1656,743194,3,1,,144213967,1923,Inconclusive,,,6.1645,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1657,743199,2,1,,144210184,1923,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1658,743199,2,1,,144213967,1923,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1659,743202,4,1,,144210184,1923,Active,20149576.0,4780.0,6.1442,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1660,743202,4,1,,144213967,1923,Inconclusive,20149576.0,4780.0,6.857,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1661,743203,3,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1662,743203,3,1,,144213967,1923,Active,,,4.3277,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1663,743209,3,1,,144210184,1923,Active,,,0.8756,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1664,743209,3,1,,144213967,1923,Active,,,0.1548,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1665,743210,4,1,,144210184,1923,Inconclusive,4504517.0,3315.0,0.7803,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1666,743210,4,1,,144213967,1923,Inconclusive,4504517.0,3315.0,0.2454,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1667,743211,3,1,,144210184,1923,Inconclusive,,,0.6955,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1668,743211,3,1,,144213967,1923,Active,,,0.1549,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1669,743212,3,1,,144210184,1923,Inconclusive,216409690.0,5467.0,1.3877,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1670,743212,3,1,,144213967,1923,Inconclusive,216409690.0,5467.0,0.6164,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1671,743213,3,1,,144210184,1923,Inconclusive,,,1.1023,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1672,743213,3,1,,144213967,1923,Active,,,0.1549,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1673,743215,3,1,,144210184,1923,Inconclusive,216409690.0,5467.0,0.5524,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1674,743215,3,1,,144213967,1923,Inconclusive,216409690.0,5467.0,0.3467,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1675,743217,3,1,,144210184,1923,Inconclusive,325495553.0,9971.0,17.4696,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1676,743217,3,1,,144213967,1923,Inconclusive,325495553.0,9971.0,0.5494,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1677,743218,3,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1678,743218,3,1,,144213967,1923,Active,,,0.3467,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1679,743219,3,1,,144210184,1923,Active,20149576.0,4780.0,9.73783,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1680,743219,3,1,,144213967,1923,Active,20149576.0,4780.0,63.827,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1681,743220,3,1,,144210184,1923,Inconclusive,325495553.0,9971.0,0.8756,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1682,743220,3,1,,144213967,1923,Inconclusive,325495553.0,9971.0,0.4897,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1683,743221,3,1,,144210184,1923,Inconclusive,,,19.6012,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1684,743221,3,1,,144213967,1923,Active,,,0.7761,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1685,743222,3,1,,144210184,1923,Inconclusive,216409708.0,7421.0,1.557,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1686,743222,3,1,,144213967,1923,Inconclusive,216409708.0,7421.0,0.1549,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1687,743223,3,1,,144210184,1923,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1688,743223,3,1,,144213967,1923,Inconclusive,216409708.0,7421.0,9.77,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1689,743224,3,1,,144210184,1923,Active,,,0.2468,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1690,743224,3,1,,144213967,1923,Active,,,0.1096,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1691,743225,3,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1692,743225,3,1,,144213967,1923,Active,,,8.7076,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1693,743226,2,1,,144210184,1923,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1694,743226,2,1,,144213967,1923,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1695,743227,2,1,,144210184,1923,Inconclusive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1696,743227,2,1,,144213967,1923,Inconclusive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1697,743228,3,1,,144210184,1923,Active,4504517.0,3315.0,0.20762600000000003,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1698,743228,3,1,,144213967,1923,Active,4504517.0,3315.0,0.309262,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1699,743239,2,1,,144210184,1923,Inconclusive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1700,743239,2,1,,144213967,1923,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1701,743240,2,1,,144210184,1923,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1702,743240,2,1,,144213967,1923,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1703,743241,2,1,,144210184,1923,Inconclusive,216409708.0,7421.0,0.310658,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1704,743241,2,1,,144213967,1923,Inconclusive,216409708.0,7421.0,0.37919,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1705,743242,2,1,,144210184,1923,Active,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1706,743242,2,1,,144213967,1923,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1707,743244,1,1,,144206634,1923,Active,,,11.2202,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1708,743244,1,1,,144213967,1923,Active,,,25.1189,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1709,743269,1,1,,99355760,1923,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1710,743269,1,1,,99355760,1923,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1711,743288,1,1,,17389213,1923,Inconclusive,,,79.4328,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
1712,743288,1,1,,17389852,1923,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
1713,743292,1,1,,17389213,1923,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
1714,743292,1,1,,17389852,1923,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
1715,743398,1,1,,99355760,1923,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
1716,760043,1,1,,103284327,1923,Unspecified,,,,,Antibacterial activity against Burkholderia thailandensis E264 assessed as bacterial growth inhibition at 1 mM after 24 hrs by two-fold dilution method relative to DMSO-treated control,Other,24376907.0,
1717,760045,2,3,,103284327,1923,Active,1703273.0,10988.0,2.03,IC50,Inhibition of human methionine aminopeptidase 2,Confirmatory,24376907.0,
1718,760046,3,2,,103284327,1923,Unspecified,33302602.0,23173.0,15.0,IC50,Inhibition of human methionine aminopeptidase 1,Confirmatory,24376907.0,
1719,760047,1,1,,103284327,1923,Unspecified,,,250.0,IC50,Inhibition of Burkholderia pseudomallei recombinant methionine aminopeptidase 1 using H-Met-Gly-Pro-7-amino-4-methylcoumarin hydrochloride as substrate measured for 10 mins by fluorescence assay in presence of human recombinant DPP4,Confirmatory,24376907.0,
1720,936940,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020909,Other,,
1721,936941,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020909,Other,,
1722,936942,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020909,Other,,
1723,936943,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020909,Other,,
1724,936944,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020909,Other,,
1725,936945,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020909,Other,,
1726,936946,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020909,Other,,
1727,936947,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020909",Other,,
1728,936948,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020909,Other,,
1729,936949,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020909,Other,,
1730,936950,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020909,Other,,
1731,936951,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020909,Other,,
1732,936952,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020909,Other,,
1733,936953,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020909,Other,,
1734,936954,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020909,Other,,
1735,936955,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020909,Other,,
1736,936956,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020909,Other,,
1737,936957,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020909,Other,,
1738,937588,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020909,Other,,
1739,943175,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020909,Other,,
1740,943176,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020909,Other,,
1741,943177,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020909",Other,,
1742,943178,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020909,Other,,
1743,943179,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020909,Other,,
1744,943180,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020909,Other,,
1745,943181,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020909,Other,,
1746,943182,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020909,Other,,
1747,943183,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020909,Other,,
1748,943184,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020909,Other,,
1749,943185,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020909,Other,,
1750,943186,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020909,Other,,
1751,943187,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020909,Other,,
1752,943188,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020909,Other,,
1753,943189,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020909,Other,,
1754,943190,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020909,Other,,
1755,943191,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020909,Other,,
1756,943192,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020909,Other,,
1757,943193,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020909,Other,,
1758,949569,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020909,Other,,
1759,949570,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020909,Other,,
1760,949571,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020909,Other,,
1761,949572,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020909,Other,,
1762,949573,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020909,Other,,
1763,949574,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020909,Other,,
1764,949575,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020909,Other,,
1765,949576,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020909,Other,,
1766,949577,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020909,Other,,
1767,949578,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020909,Other,,
1768,949579,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020909,Other,,
1769,949580,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020909,Other,,
1770,949581,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020909,Other,,
1771,949582,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020909,Other,,
1772,949583,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020909,Other,,
1773,949584,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020909,Other,,
1774,949585,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020909,Other,,
1775,949586,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020909,Other,,
1776,949587,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020909,Other,,
1777,970146,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020909,Other,,
1778,972167,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020909,Other,,
1779,972168,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020909,Other,,
1780,972169,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020909,Other,,
1781,972170,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020909,Other,,
1782,972171,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020909,Other,,
1783,972172,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020909,Other,,
1784,972173,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020909,Other,,
1785,972174,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020909,Other,,
1786,972175,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020909,Other,,
1787,972176,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020909,Other,,
1788,972177,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020909,Other,,
1789,972178,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020909,Other,,
1790,972809,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020909,Other,,
1791,972810,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020909,Other,,
1792,972811,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020909,Other,,
1793,972812,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020909,Other,,
1794,972813,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020909,Other,,
1795,972814,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020909,Other,,
1796,977610,3,1,,170484495,1923,Active,385867656.0,,0.58,Ki,Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB,Other,22311113.0,
1797,1000193,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020909",Other,,
1798,1000194,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020909",Other,,
1799,1000775,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020909",Other,,
1800,1000776,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020909",Other,,
1801,1000777,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020909",Other,,
1802,1000778,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020909",Other,,
1803,1000779,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020909,Other,,
1804,1000780,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020909",Other,,
1805,1000781,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020909,Other,,
1806,1000782,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020909",Other,,
1807,1000783,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020909",Other,,
1808,1000784,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020909",Other,,
1809,1000785,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020909",Other,,
1810,1000786,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020909",Other,,
1811,1000787,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020909",Other,,
1812,1000788,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020909",Other,,
1813,1000789,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020909",Other,,
1814,1000790,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020909",Other,,
1815,1000791,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020909",Other,,
1816,1000792,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020909",Other,,
1817,1000793,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020909",Other,,
1818,1000794,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020909",Other,,
1819,1000795,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020909",Other,,
1820,1000796,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020909",Other,,
1821,1000797,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020909",Other,,
1822,1002660,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020909",Other,,
1823,1002661,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020909",Other,,
1824,1002662,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020909",Other,,
1825,1002663,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020909",Other,,
1826,1002664,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020909,Other,,
1827,1002665,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020909,Other,,
1828,1002666,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020909",Other,,
1829,1002667,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020909",Other,,
1830,1002668,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020909",Other,,
1831,1002669,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020909",Other,,
1832,1002670,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020909,Other,,
1833,1003256,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020909",Other,,
1834,1003257,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020909",Other,,
1835,1003258,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020909",Other,,
1836,1003259,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020909",Other,,
1837,1003260,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020909,Other,,
1838,1003261,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020909",Other,,
1839,1003262,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020909",Other,,
1840,1003263,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020909",Other,,
1841,1003264,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020909",Other,,
1842,1003265,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020909",Other,,
1843,1003266,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020909",Other,,
1844,1003267,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020909",Other,,
1845,1003268,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020909,Other,,
1846,1003269,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020909",Other,,
1847,1003270,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020909",Other,,
1848,1003271,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020909",Other,,
1849,1003272,1,3,,103284327,1923,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020909,Other,,
1850,1003273,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020909",Other,,
1851,1003274,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020909",Other,,
1852,1003275,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020909",Other,,
1853,1003276,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020909",Other,,
1854,1003277,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020909",Other,,
1855,1003278,1,3,,103284327,1923,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020909",Other,,
1856,1053197,1,1,,99355760,1923,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
1857,1068575,2,3,,103284327,1923,Unspecified,399133.0,,30.0,IC50,Inhibition of Clostridium botulinum BoNT/A LC expressed in Escherichia coli assessed as cleavage of SNAPtide preincubated for 5 mins followed by SNAPtide addition measured for 105 mins by fluorescence assay,Confirmatory,24387280.0,
1858,1117267,1,1,,99355760,1923,Inactive,48145933.0,7276.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of Transthyretin (TTR) transcription,Screening,,
1859,1117298,1,2,,144213967,1923,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
1860,1117304,1,2,,144213967,1923,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
1861,1117305,1,2,,144213967,1923,Inactive,,,3.1623,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
1862,1117310,1,1,,144213967,1923,Inactive,,,3.16228,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
1863,1117312,1,1,,144213967,1923,Inactive,,,3.16228,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
1864,1117314,1,1,,144213967,1923,Inactive,,,70.7946,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
1865,1136964,2,1,,103284327,1923,Unspecified,,,,,"1-Octanol-water partition coefficient, log P of the compound by spectrophotometer analysis",Other,401891.0,
1866,1136965,1,1,,103284327,1923,Unspecified,,,,,"Ionization constant, pKa of 8-hydroxyl group of the compound at 1 mM by potentiometric analysis",Other,401891.0,
1867,1136966,1,1,,103284327,1923,Unspecified,,,,,"Ionization constant, pKa of quinoline nitrogen group of the compound at 1 mM by potentiometric analysis",Other,401891.0,
1868,1136967,1,1,,103284327,1923,Unspecified,,,,,"Ionization constant, pKa of substituent at 5th position of the compound at 1 mM by potentiometric analysis",Other,401891.0,
1869,1136969,2,1,,103284327,1923,Unspecified,,,,,"1-Octanol-water partition coefficient, log P of the compound by spectrophotometer analysis corrected for ionization",Other,401891.0,
1870,1148945,2,1,,103284327,1923,Unspecified,,,,,"1-Octanol-water partition coefficient, log P of the compound after 90 mins",Other,812992.0,
1871,1148946,1,1,,103284327,1923,Unspecified,,,,,Antibacterial activity against Streptococcus mutans 6715 assessed as inhibition of plaque formation in human teeth at 10'-1 M after 24 hrs,Other,812992.0,
1872,1148947,1,1,,103284327,1923,Unspecified,,,,,Antibacterial activity against Streptococcus mutans 6715 assessed as inhibition of plaque formation in human teeth at 10'-1 M after 48 hrs,Other,812992.0,
1873,1148948,1,1,,103284327,1923,Unspecified,,,,,Antibacterial activity against Streptococcus mutans 6715 assessed as inhibition of plaque formation in human teeth at 10'-2 M after 24 hrs,Other,812992.0,
1874,1148949,1,1,,103284327,1923,Unspecified,,,,,Antibacterial activity against Streptococcus mutans 6715 assessed as inhibition of plaque formation in human teeth at 10'-2 M after 48 hrs,Other,812992.0,
1875,1149251,2,2,,103284327,1923,Active,116909.0,24267.0,21.3796,IC50,Inhibition of Sprague-Dawley rat liver COMT after 10 mins using 0.05 uCi [14CH3]-SAM as substrate,Confirmatory,817025.0,
1876,1159509,1,1,,144210184,1923,Inconclusive,119626539.0,4790.0,3.1066,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1877,1159509,1,1,,144213967,1923,Inconclusive,119626539.0,4790.0,0.2187,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1878,1159515,1,1,,144210184,1923,Inconclusive,,,5.5244,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1879,1159515,1,1,,144213967,1923,Active,,,0.977,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1880,1159516,1,1,,144210184,1923,Inconclusive,119611100.0,22926.0,0.1747,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1881,1159516,1,1,,144213967,1923,Inconclusive,119611100.0,22926.0,0.0549,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1882,1159517,1,1,,144210184,1923,Active,,,0.7803,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1883,1159517,1,1,,144213967,1923,Active,,,0.1548,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1884,1159518,1,1,,144210184,1923,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1885,1159518,1,1,,144213967,1923,Inconclusive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1886,1159519,1,1,,144210184,1923,Inconclusive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1887,1159519,1,1,,144213967,1923,Inconclusive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1888,1159520,1,1,,144210184,1923,Inconclusive,,,9.7378,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1889,1159520,1,1,,144213967,1923,Active,,,3.4376,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1890,1159521,1,1,,144210184,1923,Active,15928672.0,19885.0,0.7735,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1891,1159521,1,1,,144213967,1923,Active,15928672.0,19885.0,0.8635,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1892,1159523,1,1,,144210184,1923,Inconclusive,15928672.0,19885.0,0.867885,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1893,1159523,1,1,,144213967,1923,Active,15928672.0,19885.0,1.8853400000000002,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1894,1159525,1,1,,144210184,1923,Inconclusive,,,5.5244,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1895,1159525,1,1,,144213967,1923,Active,,,1.23,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1896,1159526,1,1,,144210184,1923,Inconclusive,119627033.0,3725.0,0.3911,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1897,1159526,1,1,,144213967,1923,Inconclusive,119627033.0,3725.0,0.6917,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1898,1159527,1,1,,144210184,1923,Inconclusive,325495497.0,6256.0,1.9601,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1899,1159527,1,1,,144213967,1923,Inconclusive,325495497.0,6256.0,1.23,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1900,1159528,1,1,,144210184,1923,Active,119627033.0,3725.0,0.10405999999999999,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1901,1159528,1,1,,144213967,1923,Inconclusive,119627033.0,3725.0,0.424041,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1902,1159529,1,1,,144210184,1923,Active,,,0.7803,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1903,1159529,1,1,,144213967,1923,Active,,,0.6917,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1904,1159531,1,1,,144210184,1923,Inconclusive,325495497.0,6256.0,0.58517,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1905,1159531,1,1,,144213967,1923,Inconclusive,325495497.0,6256.0,1.24584,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1906,1159551,1,1,,144210184,1923,Inconclusive,,,6.1442,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1907,1159551,1,1,,144213967,1923,Active,,,7.6959,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1908,1159552,1,1,,144210184,1923,Inactive,325495463.0,5914.0,0.2744,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1909,1159552,1,1,,144213967,1923,Inactive,325495463.0,5914.0,0.2434,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1910,1159553,2,1,,144210184,1923,Inconclusive,325495463.0,5914.0,0.1732,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1911,1159553,2,1,,144213967,1923,Inconclusive,325495463.0,5914.0,0.2169,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1912,1159555,1,1,,144210184,1923,Inconclusive,325495463.0,5914.0,0.18698,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1913,1159555,1,1,,144213967,1923,Inconclusive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1914,1159580,2,1,,268734653,1923,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1915,1159606,1,1,,99355760,1923,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
1916,1159607,2,1,,312995377,1923,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1917,1159614,1,2,,144213967,1923,Inactive,22328079.0,2581.0,1.5849,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
1918,1159620,1,1,,103284327,1923,Active,,,,,Summary of drug indications.,Other,,
1919,1182518,1,1,,103284327,1923,Active,,,,,Radioprotective activity against gamma-irradiated human MOLT4 cells preincubated for 1 hr at <50 uM before gamma-irradiation measured after 18 hrs by erythrosine B dye-exclusion test,Other,25002230.0,
1920,1182520,1,2,,103284327,1923,Unspecified,,,,,Cytotoxicity against human MOLT4 cells at 100 to 400 uM after 18 hrs by erythrosine B dye-exclusion test,Other,25002230.0,
1921,1198409,1,1,,103284327,1923,Unspecified,,,,,Anticandidal activity against Candida albicans ATCC 90028 incubated at 37 degC for 24 hrs by broth dilution method,Other,25686593.0,
1922,1198410,1,1,,103284327,1923,Unspecified,,,,,Fungicidal activity against Candida albicans ATCC 90028 incubated at 37 degC for 48 hrs by broth dilution method,Other,25686593.0,
1923,1198411,1,1,,103284327,1923,Unspecified,,,,,Anticandidal activity against Candida glabrata ATCC 90030 incubated at 37 degC for 24 hrs by broth dilution method,Other,25686593.0,
1924,1198412,1,1,,103284327,1923,Unspecified,,,,,Fungicidal activity against Candida glabrata ATCC 90030 incubated at 37 degC for 48 hrs by broth dilution method,Other,25686593.0,
1925,1198413,1,1,,103284327,1923,Unspecified,,,,,Anticandidal activity against Candida tropicalis ATCC 750 incubated at 37 degC for 24 hrs by broth dilution method,Other,25686593.0,
1926,1198414,1,1,,103284327,1923,Unspecified,,,,,Fungicidal activity against Candida tropicalis ATCC 750 incubated at 37 degC for 48 hrs by broth dilution method,Other,25686593.0,
1927,1198415,1,1,,103284327,1923,Inconclusive,,,,,Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by neutral red assay,Other,25686593.0,
1928,1198426,1,1,,103284327,1923,Unspecified,,,,,Toxicity in human RBC assessed as induction of hemolysis at 500 ug/ml incubated for 1 hr by spectrophotometry,Other,25686593.0,
1929,1198427,1,1,,103284327,1923,Unspecified,,,,,Toxicity in human RBC assessed as induction of hemolysis at anticandidal IC50 level incubated for 1 hr by spectrophotometry,Other,25686593.0,
1930,1224818,1,1,,144213967,1923,Inconclusive,,,48.5577,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
1931,1224819,1,1,,144213967,1923,Inconclusive,325495545.0,2101.0,43.2771,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
1932,1224820,1,1,,144213967,1923,Inactive,325495545.0,2101.0,43.2771,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
1933,1224821,1,1,,144213967,1923,Active,325495545.0,2101.0,1.9331,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
1934,1224822,1,1,,144213967,1923,Active,,,0.7696,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
1935,1224823,1,1,,144213967,1923,Inactive,325495545.0,2101.0,1.9331,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
1936,1224834,3,1,,144210184,1923,Active,,,2.7445,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1937,1224834,3,1,,144213967,1923,Active,,,2.4337,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1938,1224835,1,1,,144210184,1923,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1939,1224835,1,1,,144213967,1923,Inconclusive,160794.0,,70.9799,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1940,1224836,1,1,,144210184,1923,Active,,,13.755,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1941,1224836,1,1,,144213967,1923,Active,,,3.8571,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1942,1224837,1,1,,144210184,1923,Active,,,2.18,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1943,1224837,1,1,,144213967,1923,Active,,,0.8635,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1944,1224838,1,1,,144210184,1923,Active,66775687.0,9970.0,1.3755,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1945,1224838,1,1,,144213967,1923,Active,66775687.0,9970.0,0.7696,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1946,1224839,1,1,,144210184,1923,Inactive,66775687.0,9970.0,13.755,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1947,1224839,1,1,,144213967,1923,Inactive,66775687.0,9970.0,6.1131,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1948,1224840,3,1,,144210184,1923,Inconclusive,,,13.755,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1949,1224840,3,1,,144213967,1923,Active,,,2.4337,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1950,1224841,3,1,,144210184,1923,Active,325495545.0,2101.0,27.4449,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1951,1224841,3,1,,144213967,1923,Active,325495545.0,2101.0,13.6854,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1952,1224842,3,1,,144210184,1923,Inactive,325495545.0,2101.0,27.4449,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1953,1224842,3,1,,144213967,1923,Inactive,325495545.0,2101.0,13.6854,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1954,1224843,1,1,,144210184,1923,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1955,1224843,1,1,,144213967,1923,Inconclusive,119601739.0,7253.0,0.6113,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1956,1224844,1,1,,144210184,1923,Inconclusive,,,9.8239,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1957,1224844,1,1,,144213967,1923,Active,,,1.0962,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1958,1224845,1,1,,144210184,1923,Active,344243002.0,100757539.0,1.4304,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1959,1224845,1,1,,144213967,1923,Inconclusive,344243002.0,100757539.0,4.4988,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1960,1224846,1,1,,144210184,1923,Inconclusive,11995455.0,3091.0,0.4388,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1961,1224846,1,1,,144213967,1923,Inconclusive,11995455.0,3091.0,0.977,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1962,1224847,1,1,,144210184,1923,Inconclusive,,,90.2551,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1963,1224847,1,1,,144213967,1923,Inconclusive,,,3.5735,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1964,1224848,3,1,,144210184,1923,Active,325495545.0,2101.0,2.7445,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1965,1224848,3,1,,144213967,1923,Active,325495545.0,2101.0,5.4483,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1966,1224849,3,1,,144210184,1923,Inactive,325495545.0,2101.0,2.4459999999999997,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1967,1224849,3,1,,144213967,1923,Inactive,325495545.0,2101.0,4.8558,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1968,1224857,2,1,,144213967,1923,Inconclusive,,,50.1187,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1969,1224859,2,1,,144213967,1923,Inactive,,,70.7946,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1970,1224863,1,1,,316919656,1923,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1971,1224865,1,2,,99355760,1923,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
1972,1224867,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1973,1224867,1,1,,144213967,1923,Active,,,3.4665,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1974,1224868,1,1,,144210184,1923,Inconclusive,,,13.8766,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1975,1224868,1,1,,144213967,1923,Active,,,5.4941,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1976,1224869,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1977,1224869,1,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1978,1224870,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1979,1224870,1,1,,144213967,1923,Active,,,3.0896,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1980,1224871,1,1,,144210184,1923,Active,,,11.0226,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1981,1224871,1,1,,144213967,1923,Active,,,2.1872,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1982,1224872,1,1,,144210184,1923,Inconclusive,,,11.0226,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1983,1224872,1,1,,144213967,1923,Inconclusive,,,5.4941,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1984,1224873,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1985,1224873,1,1,,144213967,1923,Inconclusive,,,3.0896,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1986,1224874,1,1,,144210184,1923,Active,,,13.8766,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1987,1224874,1,1,,144213967,1923,Active,,,5.4941,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1988,1224875,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1989,1224875,1,1,,144213967,1923,Inconclusive,,,6.1645,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1990,1224876,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1991,1224876,1,1,,144213967,1923,Active,,,6.1645,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1992,1224877,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1993,1224877,1,1,,144213967,1923,Active,,,3.0896,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1994,1224878,1,1,,144210184,1923,Active,,,9.8239,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1995,1224878,1,1,,144213967,1923,Active,,,3.4665,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1996,1224879,1,1,,144210184,1923,Active,,,9.8239,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1997,1224879,1,1,,144213967,1923,Active,,,2.1872,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1998,1224880,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1999,1224880,1,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
2000,1224881,1,1,,144210184,1923,Active,,,17.4696,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
2001,1224881,1,1,,144213967,1923,Active,,,6.1645,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
2002,1224882,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
2003,1224882,1,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
2004,1224883,1,1,,144210184,1923,Active,,,9.8239,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
2005,1224883,1,1,,144213967,1923,Active,,,2.1872,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
2006,1224884,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
2007,1224884,1,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
2008,1224885,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
2009,1224885,1,1,,144213967,1923,Active,,,3.8895,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
2010,1224886,1,1,,144210184,1923,Inconclusive,,,12.3675,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
2011,1224886,1,1,,144213967,1923,Active,,,5.4941,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
2012,1224887,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
2013,1224887,1,1,,144213967,1923,Inconclusive,,,43.6465,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
2014,1224888,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
2015,1224888,1,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
2016,1224889,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
2017,1224889,1,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
2018,1224890,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
2019,1224890,1,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
2020,1224892,1,1,,144210184,1923,Inconclusive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2021,1224892,1,1,,144213967,1923,Inconclusive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2022,1224893,1,1,,144210184,1923,Inconclusive,66775687.0,9970.0,2.01896,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2023,1224893,1,1,,144213967,1923,Inconclusive,66775687.0,9970.0,2.35262,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2024,1224894,1,1,,144210184,1923,Inconclusive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
2025,1224894,1,1,,144213967,1923,Inconclusive,11995455.0,3091.0,3.62201,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
2026,1224895,1,1,,144210184,1923,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
2027,1224895,1,1,,144213967,1923,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
2028,1224896,1,1,,144210184,1923,Active,344243002.0,100757539.0,0.716921,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
2029,1224896,1,1,,144213967,1923,Active,344243002.0,100757539.0,2.66131,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
2030,1249021,1,1,,103284327,1923,Active,399037.0,,0.16,Ki,Inhibition of Aeromonas proteolytica aminopeptidase assessed as hydrolysis of LeuNA at pH 8 by spectrophotometric analysis,Confirmatory,,
2031,1255354,1,1,,103284327,1923,Active,,,,,Ionophoric activity in human SH-SY5Y cells assessed as increase in cellular Cu uptake at 20 uM after 6 hrs by ICP-MS analysis relative to vehicle-treated control,Other,26396692.0,
2032,1255355,1,1,,103284327,1923,Inactive,,,,,Ionophoric activity in human SH-SY5Y cells assessed as increase in cellular Zn uptake at 20 uM after 6 hrs by ICP-MS analysis relative to vehicle-treated control,Other,26396692.0,
2033,1255356,1,1,,103284327,1923,Inactive,,,,,Ionophoric activity in human SH-SY5Y cells assessed as increase in cellular Fe uptake at 20 uM after 6 hrs by ICP-MS analysis relative to vehicle-treated control,Other,26396692.0,
2034,1259241,1,1,,144210184,1923,Inconclusive,,,3.0794,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
2035,1259241,1,1,,144213967,1923,Active,,,1.9331,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
2036,1259242,1,1,,144210184,1923,Inconclusive,,,3.0794,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
2037,1259242,1,1,,144213967,1923,Inconclusive,,,5.4483,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
2038,1259243,1,1,,144210184,1923,Active,124375976.0,367.0,3.0794,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
2039,1259243,1,1,,144213967,1923,Active,124375976.0,367.0,2.4337,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
2040,1259244,1,1,,144210184,1923,Active,348019627.0,2099.0,1.2259,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
2041,1259244,1,1,,144213967,1923,Active,348019627.0,2099.0,0.6859,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
2042,1259247,1,1,,144210184,1923,Inconclusive,124375976.0,367.0,2.6411599999999997,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
2043,1259247,1,1,,144213967,1923,Inconclusive,124375976.0,367.0,4.63095,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
2044,1259248,1,1,,144210184,1923,Inconclusive,348019627.0,2099.0,1.60372,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
2045,1259248,1,1,,144213967,1923,Inconclusive,348019627.0,2099.0,4.12343,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
2046,1259318,1,1,,99355760,1923,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
2047,1259344,1,1,,144206634,1923,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
2048,1259344,1,1,,144213967,1923,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
2049,1259364,1,1,,144210184,1923,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
2050,1259364,1,1,,144213967,1923,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
2051,1259365,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
2052,1259365,1,1,,144213967,1923,Inconclusive,,,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
2053,1259366,1,1,,144210184,1923,Active,,,0.6894,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2054,1259366,1,1,,144213967,1923,Active,,,0.4856,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2055,1259367,1,1,,144210184,1923,Active,,,1.0926,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2056,1259367,1,1,,144213967,1923,Active,,,0.4328,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2057,1259368,1,1,,144210184,1923,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2058,1259368,1,1,,144213967,1923,Inactive,109731339.0,2737.0,0.3857,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2059,1259369,1,1,,144210184,1923,Active,109731339.0,2737.0,0.435,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2060,1259369,1,1,,144213967,1923,Active,109731339.0,2737.0,0.122,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2061,1259377,1,1,,144210184,1923,Inconclusive,54288833.0,2100.0,7.735,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2062,1259377,1,1,,144213967,1923,Inconclusive,54288833.0,2100.0,1.3685,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2063,1259378,1,1,,144210184,1923,Inconclusive,54288833.0,2100.0,12.2592,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2064,1259378,1,1,,144213967,1923,Inconclusive,54288833.0,2100.0,4.8558,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2065,1259379,1,1,,144210184,1923,Active,,,6.1442,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2066,1259379,1,1,,144213967,1923,Active,,,9.6885,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2067,1259380,1,1,,144210184,1923,Active,,,1.3755,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2068,1259380,1,1,,144213967,1923,Active,,,1.2197,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2069,1259381,1,1,,144210184,1923,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
2070,1259381,1,1,,144213967,1923,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
2071,1259382,1,1,,144210184,1923,Inconclusive,,,1.7317,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2072,1259382,1,1,,144213967,1923,Inconclusive,,,1.0871,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2073,1259383,1,1,,144210184,1923,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
2074,1259383,1,1,,144213967,1923,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
2075,1259384,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
2076,1259384,1,1,,144213967,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
2077,1259385,1,1,,144210184,1923,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2078,1259385,1,1,,144213967,1923,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2079,1259386,1,1,,144210184,1923,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2080,1259386,1,1,,144213967,1923,Inconclusive,,,9.6885,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2081,1259387,1,1,,144210184,1923,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
2082,1259387,1,1,,144213967,1923,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
2083,1259388,1,1,,144210184,1923,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
2084,1259388,1,1,,144213967,1923,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
2085,1259390,1,1,,144210184,1923,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2086,1259390,1,1,,144213967,1923,Inconclusive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2087,1259391,1,1,,144210184,1923,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
2088,1259391,1,1,,144213967,1923,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
2089,1259392,1,1,,144210184,1923,Inconclusive,109731339.0,2737.0,0.488047,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2090,1259392,1,1,,144213967,1923,Inconclusive,109731339.0,2737.0,0.46323800000000004,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2091,1259393,1,1,,144210184,1923,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
2092,1259393,1,1,,144213967,1923,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
2093,1259394,1,1,,144210184,1923,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2094,1259394,1,1,,144213967,1923,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2095,1259395,1,1,,144210184,1923,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
2096,1259395,1,1,,144213967,1923,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
2097,1259396,1,1,,144210184,1923,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2098,1259396,1,1,,144213967,1923,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2099,1259400,1,1,,124889868,1923,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
2100,1259401,1,1,,144210184,1923,Inconclusive,325495545.0,2101.0,28.5186,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2101,1259401,1,1,,144213967,1923,Inconclusive,325495545.0,2101.0,22.0572,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2102,1259402,1,1,,144210184,1923,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2103,1259402,1,1,,144213967,1923,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2104,1259403,1,1,,144210184,1923,Inconclusive,325495545.0,2101.0,2.96343,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2105,1259403,1,1,,144213967,1923,Inconclusive,325495545.0,2101.0,5.8564,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2106,1259404,1,1,,144210184,1923,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2107,1259404,1,1,,144213967,1923,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2108,1259407,1,1,,363898290,1923,Active,,,,,CCRIS mutagenicity studies,Other,,
2109,1259408,1,1,,363895491,1923,Inactive,,,,,GENE-TOX mutagenicity studies,Other,,
2110,1259411,1,1,,363898290,1923,Inactive,,,,,CCRIS carcinogenicity studies,Other,,
2111,1259416,1,2,,340079419,1923,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
2112,1259421,1,1,,340079419,1923,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
2113,1259423,1,2,,354911503,1923,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
